Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,16398336,maximum levels,"Cortisol peaked at 20 min after administration of CRH in both cycling gilts and castrated boars with maximum levels of 149.3 +/- 16.5 nmol/l and 138.3 +/- 10.1 nmol/l, respectively.",Effect of ACTH and CRH on plasma levels of cortisol and prostaglandin F2alpha metabolite in cycling gilts and castrated boars. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16398336/),[nM] / [l],149.3,1623,DB01285,Corticotropin
,16398336,maximum levels,"Cortisol peaked at 20 min after administration of CRH in both cycling gilts and castrated boars with maximum levels of 149.3 +/- 16.5 nmol/l and 138.3 +/- 10.1 nmol/l, respectively.",Effect of ACTH and CRH on plasma levels of cortisol and prostaglandin F2alpha metabolite in cycling gilts and castrated boars. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16398336/),[nM] / [l],138.3,1624,DB01285,Corticotropin
,12236849,Fifty percent inhibitory concentrations (IC50),"Fifty percent inhibitory concentrations (IC50) of 0.82, 1.48, 1.31 and 0.88 micro g ml(-1), zero-order rate constants for the onset of plasma DHT concentration changes (kin) of 17.8, 17.4, 17.0 and 10.7% h(-1) and first-order rate constants for increase in plasma DHT concentrations to basal values (kout) of 0.17, 0.16, 0.17 and 0.10 h(-1) for the single study at doses of 25, 50, 75 and 100 mg, respectively, were attained.","Pharmacokinetics and pharmacodynamics of TF-505, a novel nonsteroidal 5alpha-reductase inhibitor, in normal subjects treated with single or multiple doses. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12236849/),[μg] / [ml],0.82,5456,DB01285,Corticotropin
,12236849,Fifty percent inhibitory concentrations (IC50),"Fifty percent inhibitory concentrations (IC50) of 0.82, 1.48, 1.31 and 0.88 micro g ml(-1), zero-order rate constants for the onset of plasma DHT concentration changes (kin) of 17.8, 17.4, 17.0 and 10.7% h(-1) and first-order rate constants for increase in plasma DHT concentrations to basal values (kout) of 0.17, 0.16, 0.17 and 0.10 h(-1) for the single study at doses of 25, 50, 75 and 100 mg, respectively, were attained.","Pharmacokinetics and pharmacodynamics of TF-505, a novel nonsteroidal 5alpha-reductase inhibitor, in normal subjects treated with single or multiple doses. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12236849/),[μg] / [ml],1.48,5457,DB01285,Corticotropin
,12236849,Fifty percent inhibitory concentrations (IC50),"Fifty percent inhibitory concentrations (IC50) of 0.82, 1.48, 1.31 and 0.88 micro g ml(-1), zero-order rate constants for the onset of plasma DHT concentration changes (kin) of 17.8, 17.4, 17.0 and 10.7% h(-1) and first-order rate constants for increase in plasma DHT concentrations to basal values (kout) of 0.17, 0.16, 0.17 and 0.10 h(-1) for the single study at doses of 25, 50, 75 and 100 mg, respectively, were attained.","Pharmacokinetics and pharmacodynamics of TF-505, a novel nonsteroidal 5alpha-reductase inhibitor, in normal subjects treated with single or multiple doses. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12236849/),[μg] / [ml],1.31,5458,DB01285,Corticotropin
,12236849,Fifty percent inhibitory concentrations (IC50),"Fifty percent inhibitory concentrations (IC50) of 0.82, 1.48, 1.31 and 0.88 micro g ml(-1), zero-order rate constants for the onset of plasma DHT concentration changes (kin) of 17.8, 17.4, 17.0 and 10.7% h(-1) and first-order rate constants for increase in plasma DHT concentrations to basal values (kout) of 0.17, 0.16, 0.17 and 0.10 h(-1) for the single study at doses of 25, 50, 75 and 100 mg, respectively, were attained.","Pharmacokinetics and pharmacodynamics of TF-505, a novel nonsteroidal 5alpha-reductase inhibitor, in normal subjects treated with single or multiple doses. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12236849/),[μg] / [ml],0.88,5459,DB01285,Corticotropin
,12236849,zero-order rate constants,"Fifty percent inhibitory concentrations (IC50) of 0.82, 1.48, 1.31 and 0.88 micro g ml(-1), zero-order rate constants for the onset of plasma DHT concentration changes (kin) of 17.8, 17.4, 17.0 and 10.7% h(-1) and first-order rate constants for increase in plasma DHT concentrations to basal values (kout) of 0.17, 0.16, 0.17 and 0.10 h(-1) for the single study at doses of 25, 50, 75 and 100 mg, respectively, were attained.","Pharmacokinetics and pharmacodynamics of TF-505, a novel nonsteroidal 5alpha-reductase inhibitor, in normal subjects treated with single or multiple doses. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12236849/),[%] / [h],17.8,5460,DB01285,Corticotropin
,12236849,zero-order rate constants,"Fifty percent inhibitory concentrations (IC50) of 0.82, 1.48, 1.31 and 0.88 micro g ml(-1), zero-order rate constants for the onset of plasma DHT concentration changes (kin) of 17.8, 17.4, 17.0 and 10.7% h(-1) and first-order rate constants for increase in plasma DHT concentrations to basal values (kout) of 0.17, 0.16, 0.17 and 0.10 h(-1) for the single study at doses of 25, 50, 75 and 100 mg, respectively, were attained.","Pharmacokinetics and pharmacodynamics of TF-505, a novel nonsteroidal 5alpha-reductase inhibitor, in normal subjects treated with single or multiple doses. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12236849/),[%] / [h],17.4,5461,DB01285,Corticotropin
,12236849,zero-order rate constants,"Fifty percent inhibitory concentrations (IC50) of 0.82, 1.48, 1.31 and 0.88 micro g ml(-1), zero-order rate constants for the onset of plasma DHT concentration changes (kin) of 17.8, 17.4, 17.0 and 10.7% h(-1) and first-order rate constants for increase in plasma DHT concentrations to basal values (kout) of 0.17, 0.16, 0.17 and 0.10 h(-1) for the single study at doses of 25, 50, 75 and 100 mg, respectively, were attained.","Pharmacokinetics and pharmacodynamics of TF-505, a novel nonsteroidal 5alpha-reductase inhibitor, in normal subjects treated with single or multiple doses. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12236849/),[%] / [h],17.0,5462,DB01285,Corticotropin
,12236849,zero-order rate constants,"Fifty percent inhibitory concentrations (IC50) of 0.82, 1.48, 1.31 and 0.88 micro g ml(-1), zero-order rate constants for the onset of plasma DHT concentration changes (kin) of 17.8, 17.4, 17.0 and 10.7% h(-1) and first-order rate constants for increase in plasma DHT concentrations to basal values (kout) of 0.17, 0.16, 0.17 and 0.10 h(-1) for the single study at doses of 25, 50, 75 and 100 mg, respectively, were attained.","Pharmacokinetics and pharmacodynamics of TF-505, a novel nonsteroidal 5alpha-reductase inhibitor, in normal subjects treated with single or multiple doses. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12236849/),[%] / [h],10.7,5463,DB01285,Corticotropin
,12236849,kin,"Fifty percent inhibitory concentrations (IC50) of 0.82, 1.48, 1.31 and 0.88 micro g ml(-1), zero-order rate constants for the onset of plasma DHT concentration changes (kin) of 17.8, 17.4, 17.0 and 10.7% h(-1) and first-order rate constants for increase in plasma DHT concentrations to basal values (kout) of 0.17, 0.16, 0.17 and 0.10 h(-1) for the single study at doses of 25, 50, 75 and 100 mg, respectively, were attained.","Pharmacokinetics and pharmacodynamics of TF-505, a novel nonsteroidal 5alpha-reductase inhibitor, in normal subjects treated with single or multiple doses. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12236849/),[%] / [h],17.8,5464,DB01285,Corticotropin
,12236849,kin,"Fifty percent inhibitory concentrations (IC50) of 0.82, 1.48, 1.31 and 0.88 micro g ml(-1), zero-order rate constants for the onset of plasma DHT concentration changes (kin) of 17.8, 17.4, 17.0 and 10.7% h(-1) and first-order rate constants for increase in plasma DHT concentrations to basal values (kout) of 0.17, 0.16, 0.17 and 0.10 h(-1) for the single study at doses of 25, 50, 75 and 100 mg, respectively, were attained.","Pharmacokinetics and pharmacodynamics of TF-505, a novel nonsteroidal 5alpha-reductase inhibitor, in normal subjects treated with single or multiple doses. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12236849/),[%] / [h],17.4,5465,DB01285,Corticotropin
,12236849,kin,"Fifty percent inhibitory concentrations (IC50) of 0.82, 1.48, 1.31 and 0.88 micro g ml(-1), zero-order rate constants for the onset of plasma DHT concentration changes (kin) of 17.8, 17.4, 17.0 and 10.7% h(-1) and first-order rate constants for increase in plasma DHT concentrations to basal values (kout) of 0.17, 0.16, 0.17 and 0.10 h(-1) for the single study at doses of 25, 50, 75 and 100 mg, respectively, were attained.","Pharmacokinetics and pharmacodynamics of TF-505, a novel nonsteroidal 5alpha-reductase inhibitor, in normal subjects treated with single or multiple doses. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12236849/),[%] / [h],17.0,5466,DB01285,Corticotropin
,12236849,kin,"Fifty percent inhibitory concentrations (IC50) of 0.82, 1.48, 1.31 and 0.88 micro g ml(-1), zero-order rate constants for the onset of plasma DHT concentration changes (kin) of 17.8, 17.4, 17.0 and 10.7% h(-1) and first-order rate constants for increase in plasma DHT concentrations to basal values (kout) of 0.17, 0.16, 0.17 and 0.10 h(-1) for the single study at doses of 25, 50, 75 and 100 mg, respectively, were attained.","Pharmacokinetics and pharmacodynamics of TF-505, a novel nonsteroidal 5alpha-reductase inhibitor, in normal subjects treated with single or multiple doses. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12236849/),[%] / [h],10.7,5467,DB01285,Corticotropin
,12236849,first-order rate constants,"Fifty percent inhibitory concentrations (IC50) of 0.82, 1.48, 1.31 and 0.88 micro g ml(-1), zero-order rate constants for the onset of plasma DHT concentration changes (kin) of 17.8, 17.4, 17.0 and 10.7% h(-1) and first-order rate constants for increase in plasma DHT concentrations to basal values (kout) of 0.17, 0.16, 0.17 and 0.10 h(-1) for the single study at doses of 25, 50, 75 and 100 mg, respectively, were attained.","Pharmacokinetics and pharmacodynamics of TF-505, a novel nonsteroidal 5alpha-reductase inhibitor, in normal subjects treated with single or multiple doses. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12236849/),1/[h],0.17,5468,DB01285,Corticotropin
,12236849,kout),"Fifty percent inhibitory concentrations (IC50) of 0.82, 1.48, 1.31 and 0.88 micro g ml(-1), zero-order rate constants for the onset of plasma DHT concentration changes (kin) of 17.8, 17.4, 17.0 and 10.7% h(-1) and first-order rate constants for increase in plasma DHT concentrations to basal values (kout) of 0.17, 0.16, 0.17 and 0.10 h(-1) for the single study at doses of 25, 50, 75 and 100 mg, respectively, were attained.","Pharmacokinetics and pharmacodynamics of TF-505, a novel nonsteroidal 5alpha-reductase inhibitor, in normal subjects treated with single or multiple doses. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12236849/),1/[h],0.17,5469,DB01285,Corticotropin
,12236849,kout),"Fifty percent inhibitory concentrations (IC50) of 0.82, 1.48, 1.31 and 0.88 micro g ml(-1), zero-order rate constants for the onset of plasma DHT concentration changes (kin) of 17.8, 17.4, 17.0 and 10.7% h(-1) and first-order rate constants for increase in plasma DHT concentrations to basal values (kout) of 0.17, 0.16, 0.17 and 0.10 h(-1) for the single study at doses of 25, 50, 75 and 100 mg, respectively, were attained.","Pharmacokinetics and pharmacodynamics of TF-505, a novel nonsteroidal 5alpha-reductase inhibitor, in normal subjects treated with single or multiple doses. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12236849/),1/[h],0.16,5470,DB01285,Corticotropin
,12236849,kout),"Fifty percent inhibitory concentrations (IC50) of 0.82, 1.48, 1.31 and 0.88 micro g ml(-1), zero-order rate constants for the onset of plasma DHT concentration changes (kin) of 17.8, 17.4, 17.0 and 10.7% h(-1) and first-order rate constants for increase in plasma DHT concentrations to basal values (kout) of 0.17, 0.16, 0.17 and 0.10 h(-1) for the single study at doses of 25, 50, 75 and 100 mg, respectively, were attained.","Pharmacokinetics and pharmacodynamics of TF-505, a novel nonsteroidal 5alpha-reductase inhibitor, in normal subjects treated with single or multiple doses. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12236849/),1/[h],0.10,5471,DB01285,Corticotropin
,12236849,IC50s,"In the multiple-dose study, IC50s were 1.74 and 1.49 micro g ml(-1) for the 12.5 and 25 mg doses, respectively.","Pharmacokinetics and pharmacodynamics of TF-505, a novel nonsteroidal 5alpha-reductase inhibitor, in normal subjects treated with single or multiple doses. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12236849/),[μg] / [ml],1.74,5472,DB01285,Corticotropin
,12236849,IC50s,"In the multiple-dose study, IC50s were 1.74 and 1.49 micro g ml(-1) for the 12.5 and 25 mg doses, respectively.","Pharmacokinetics and pharmacodynamics of TF-505, a novel nonsteroidal 5alpha-reductase inhibitor, in normal subjects treated with single or multiple doses. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12236849/),[μg] / [ml],1.49,5473,DB01285,Corticotropin
,32325373,t1/2,Mean t1/2 was 3.51 h for macimorelin 0.5 and 1.0 mg/kg and 8.29 h for macimorelin 2.0 mg/kg; median tmax occurred at 0.5 to 0.75 h.,"Safety, tolerability, pharmacokinetics, and pharmacodynamics of macimorelin in healthy adults: Results of a single-dose, randomized controlled study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32325373/),h,3.51,8073,DB01285,Corticotropin
,32325373,t1/2,Mean t1/2 was 3.51 h for macimorelin 0.5 and 1.0 mg/kg and 8.29 h for macimorelin 2.0 mg/kg; median tmax occurred at 0.5 to 0.75 h.,"Safety, tolerability, pharmacokinetics, and pharmacodynamics of macimorelin in healthy adults: Results of a single-dose, randomized controlled study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32325373/),h,8.29,8074,DB01285,Corticotropin
,32325373,tmax,Mean t1/2 was 3.51 h for macimorelin 0.5 and 1.0 mg/kg and 8.29 h for macimorelin 2.0 mg/kg; median tmax occurred at 0.5 to 0.75 h.,"Safety, tolerability, pharmacokinetics, and pharmacodynamics of macimorelin in healthy adults: Results of a single-dose, randomized controlled study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32325373/),h,0.5 to 0.75,8075,DB01285,Corticotropin
,32325373,tmax,"GH levels increased after dosing, with a tmax of 0.75 h to 1.0 h.","Safety, tolerability, pharmacokinetics, and pharmacodynamics of macimorelin in healthy adults: Results of a single-dose, randomized controlled study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32325373/),h,0.75,8076,DB01285,Corticotropin
,32325373,tmax,"GH levels increased after dosing, with a tmax of 0.75 h to 1.0 h.","Safety, tolerability, pharmacokinetics, and pharmacodynamics of macimorelin in healthy adults: Results of a single-dose, randomized controlled study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32325373/),h,1.0,8077,DB01285,Corticotropin
,32325373,Cmax,"Mean GH Cmax was similar with the macimorelin 0.5- and 1.0-mg/kg doses (31.9 and 37.8 ng/mL, respectively) and was ~50% lower with macimorelin 2.0 mg/kg (18.4 ng/mL).","Safety, tolerability, pharmacokinetics, and pharmacodynamics of macimorelin in healthy adults: Results of a single-dose, randomized controlled study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32325373/),[ng] / [ml],31.9,8078,DB01285,Corticotropin
,32325373,Cmax,"Mean GH Cmax was similar with the macimorelin 0.5- and 1.0-mg/kg doses (31.9 and 37.8 ng/mL, respectively) and was ~50% lower with macimorelin 2.0 mg/kg (18.4 ng/mL).","Safety, tolerability, pharmacokinetics, and pharmacodynamics of macimorelin in healthy adults: Results of a single-dose, randomized controlled study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32325373/),[ng] / [ml],37.8,8079,DB01285,Corticotropin
,32325373,Cmax,"Mean GH Cmax was similar with the macimorelin 0.5- and 1.0-mg/kg doses (31.9 and 37.8 ng/mL, respectively) and was ~50% lower with macimorelin 2.0 mg/kg (18.4 ng/mL).","Safety, tolerability, pharmacokinetics, and pharmacodynamics of macimorelin in healthy adults: Results of a single-dose, randomized controlled study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32325373/),[ng] / [ml],18.4,8080,DB01285,Corticotropin
,15341493,K(i),Compound 26 h exhibited good binding affinity at the human CRF(1) receptor with a K(i) value of 3.5 nM.,"Design of 2,5-dimethyl-3-(6-dimethyl-4-methylpyridin-3-yl)-7-dipropylaminopyrazolo[1,5-a]pyrimidine (NBI 30775/R121919) and structure--activity relationships of a series of potent and orally active corticotropin-releasing factor receptor antagonists. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15341493/),nM,3.5,13019,DB01285,Corticotropin
,15341493,IC(50),"As a functional antagonist, it dose-dependently inhibited CRF-stimulated cAMP production in cells expressing the CRF(1) receptor (IC(50) = 50 nM), and CRF-stimulated ACTH release from cultured rat pituitary cells (IC(50) = 20 nM).","Design of 2,5-dimethyl-3-(6-dimethyl-4-methylpyridin-3-yl)-7-dipropylaminopyrazolo[1,5-a]pyrimidine (NBI 30775/R121919) and structure--activity relationships of a series of potent and orally active corticotropin-releasing factor receptor antagonists. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15341493/),nM,50,13020,DB01285,Corticotropin
,15341493,IC(50),"As a functional antagonist, it dose-dependently inhibited CRF-stimulated cAMP production in cells expressing the CRF(1) receptor (IC(50) = 50 nM), and CRF-stimulated ACTH release from cultured rat pituitary cells (IC(50) = 20 nM).","Design of 2,5-dimethyl-3-(6-dimethyl-4-methylpyridin-3-yl)-7-dipropylaminopyrazolo[1,5-a]pyrimidine (NBI 30775/R121919) and structure--activity relationships of a series of potent and orally active corticotropin-releasing factor receptor antagonists. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15341493/),nM,20,13021,DB01285,Corticotropin
,15341493,log P,26 h had a log P value of 4.9 and water solubility of greater than 10 mg/mL.,"Design of 2,5-dimethyl-3-(6-dimethyl-4-methylpyridin-3-yl)-7-dipropylaminopyrazolo[1,5-a]pyrimidine (NBI 30775/R121919) and structure--activity relationships of a series of potent and orally active corticotropin-releasing factor receptor antagonists. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15341493/),,4.9,13022,DB01285,Corticotropin
greater,15341493,water solubility,26 h had a log P value of 4.9 and water solubility of greater than 10 mg/mL.,"Design of 2,5-dimethyl-3-(6-dimethyl-4-methylpyridin-3-yl)-7-dipropylaminopyrazolo[1,5-a]pyrimidine (NBI 30775/R121919) and structure--activity relationships of a series of potent and orally active corticotropin-releasing factor receptor antagonists. ",Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15341493/),[mg] / [ml],10,13023,DB01285,Corticotropin
,27301465,terminal half-life,"Pergolide effectively decreased plasma ACTH concentration in aged horses with PPID, with similar pharmacokinetic properties as reported in young horses, including an approximate terminal half-life of 24 h.",Pharmacokinetic and pharmacodynamic properties of pergolide mesylate following long-term administration to horses with pituitary pars intermedia dysfunction. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27301465/),h,24,14458,DB01285,Corticotropin
,9024262,peak level,"The expected ACTH response to oCRH was enhanced by the concomitant DP administration (peak level, 10.39 +/- 1.12 vs.",Effects of ovine corticotropin-releasing hormone injection and desmopressin coadministration on galanin and adrenocorticotropin plasma levels in normal women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9024262/),,10.39,18586,DB01285,Corticotropin
,9024262,integrated ACTH response,"The mean integrated ACTH response, expressed as the area under the curve, to SAL infusion plus oCRH injection vs. that to DP infusion plus oCRH injection was 288.23 +/- 61.94 vs. 699.70 +/- 91.80 pmol/L.60 min, respectively (P < 0.05).",Effects of ovine corticotropin-releasing hormone injection and desmopressin coadministration on galanin and adrenocorticotropin plasma levels in normal women. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9024262/),[pM] / [60·l·min],288.23,18587,DB01285,Corticotropin
,9024262,integrated ACTH response,"The mean integrated ACTH response, expressed as the area under the curve, to SAL infusion plus oCRH injection vs. that to DP infusion plus oCRH injection was 288.23 +/- 61.94 vs. 699.70 +/- 91.80 pmol/L.60 min, respectively (P < 0.05).",Effects of ovine corticotropin-releasing hormone injection and desmopressin coadministration on galanin and adrenocorticotropin plasma levels in normal women. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9024262/),[pM] / [60·l·min],699.70,18588,DB01285,Corticotropin
,9024262,area under the curve,"The mean integrated ACTH response, expressed as the area under the curve, to SAL infusion plus oCRH injection vs. that to DP infusion plus oCRH injection was 288.23 +/- 61.94 vs. 699.70 +/- 91.80 pmol/L.60 min, respectively (P < 0.05).",Effects of ovine corticotropin-releasing hormone injection and desmopressin coadministration on galanin and adrenocorticotropin plasma levels in normal women. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9024262/),[pM] / [60·l·min],288.23,18589,DB01285,Corticotropin
,9024262,area under the curve,"The mean integrated ACTH response, expressed as the area under the curve, to SAL infusion plus oCRH injection vs. that to DP infusion plus oCRH injection was 288.23 +/- 61.94 vs. 699.70 +/- 91.80 pmol/L.60 min, respectively (P < 0.05).",Effects of ovine corticotropin-releasing hormone injection and desmopressin coadministration on galanin and adrenocorticotropin plasma levels in normal women. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9024262/),[pM] / [60·l·min],699.70,18590,DB01285,Corticotropin
,10632042,Ki,"While the lead compound 1 (rCRF Ki = 44 nM) afforded no detectable rat plasma levels after intraperitoneal (i.p.) or oral (p.o.) dosing, compounds 3-3 (rCRF Ki = 16 nM) and 3-4 (rCRF Ki 59 nM) gave high rat plasma levels at 30 mg/kg (i.p., p.o.) (Cmax = 1389 nM and 8581 nM (i.p.) respectively; Cmax = 113 nM and 988 nM (p.o.), respectively).",Structure-activity studies on 4-substituted-2-anilinopyrimidine corticotropin releasing factor (CRF) antagonists. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10632042/),nM,44,20549,DB01285,Corticotropin
,10632042,Ki,"While the lead compound 1 (rCRF Ki = 44 nM) afforded no detectable rat plasma levels after intraperitoneal (i.p.) or oral (p.o.) dosing, compounds 3-3 (rCRF Ki = 16 nM) and 3-4 (rCRF Ki 59 nM) gave high rat plasma levels at 30 mg/kg (i.p., p.o.) (Cmax = 1389 nM and 8581 nM (i.p.) respectively; Cmax = 113 nM and 988 nM (p.o.), respectively).",Structure-activity studies on 4-substituted-2-anilinopyrimidine corticotropin releasing factor (CRF) antagonists. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10632042/),nM,16,20550,DB01285,Corticotropin
,10632042,Ki,"While the lead compound 1 (rCRF Ki = 44 nM) afforded no detectable rat plasma levels after intraperitoneal (i.p.) or oral (p.o.) dosing, compounds 3-3 (rCRF Ki = 16 nM) and 3-4 (rCRF Ki 59 nM) gave high rat plasma levels at 30 mg/kg (i.p., p.o.) (Cmax = 1389 nM and 8581 nM (i.p.) respectively; Cmax = 113 nM and 988 nM (p.o.), respectively).",Structure-activity studies on 4-substituted-2-anilinopyrimidine corticotropin releasing factor (CRF) antagonists. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10632042/),nM,59,20551,DB01285,Corticotropin
,10632042,Cmax,"While the lead compound 1 (rCRF Ki = 44 nM) afforded no detectable rat plasma levels after intraperitoneal (i.p.) or oral (p.o.) dosing, compounds 3-3 (rCRF Ki = 16 nM) and 3-4 (rCRF Ki 59 nM) gave high rat plasma levels at 30 mg/kg (i.p., p.o.) (Cmax = 1389 nM and 8581 nM (i.p.) respectively; Cmax = 113 nM and 988 nM (p.o.), respectively).",Structure-activity studies on 4-substituted-2-anilinopyrimidine corticotropin releasing factor (CRF) antagonists. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10632042/),nM,1389,20552,DB01285,Corticotropin
,10632042,Cmax,"While the lead compound 1 (rCRF Ki = 44 nM) afforded no detectable rat plasma levels after intraperitoneal (i.p.) or oral (p.o.) dosing, compounds 3-3 (rCRF Ki = 16 nM) and 3-4 (rCRF Ki 59 nM) gave high rat plasma levels at 30 mg/kg (i.p., p.o.) (Cmax = 1389 nM and 8581 nM (i.p.) respectively; Cmax = 113 nM and 988 nM (p.o.), respectively).",Structure-activity studies on 4-substituted-2-anilinopyrimidine corticotropin releasing factor (CRF) antagonists. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10632042/),nM,8581,20553,DB01285,Corticotropin
,10632042,Cmax,"While the lead compound 1 (rCRF Ki = 44 nM) afforded no detectable rat plasma levels after intraperitoneal (i.p.) or oral (p.o.) dosing, compounds 3-3 (rCRF Ki = 16 nM) and 3-4 (rCRF Ki 59 nM) gave high rat plasma levels at 30 mg/kg (i.p., p.o.) (Cmax = 1389 nM and 8581 nM (i.p.) respectively; Cmax = 113 nM and 988 nM (p.o.), respectively).",Structure-activity studies on 4-substituted-2-anilinopyrimidine corticotropin releasing factor (CRF) antagonists. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10632042/),nM,113,20554,DB01285,Corticotropin
,10632042,Cmax,"While the lead compound 1 (rCRF Ki = 44 nM) afforded no detectable rat plasma levels after intraperitoneal (i.p.) or oral (p.o.) dosing, compounds 3-3 (rCRF Ki = 16 nM) and 3-4 (rCRF Ki 59 nM) gave high rat plasma levels at 30 mg/kg (i.p., p.o.) (Cmax = 1389 nM and 8581 nM (i.p.) respectively; Cmax = 113 nM and 988 nM (p.o.), respectively).",Structure-activity studies on 4-substituted-2-anilinopyrimidine corticotropin releasing factor (CRF) antagonists. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10632042/),nM,988,20555,DB01285,Corticotropin
,10632042,bioavailabilities,"Furthermore 3-3 and 3-4 had superior bioavailabilities at these doses (59 and 46% (i.p.), respectively; 2 and 10%, (p.o.), respectively).",Structure-activity studies on 4-substituted-2-anilinopyrimidine corticotropin releasing factor (CRF) antagonists. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10632042/),%,59,20556,DB01285,Corticotropin
,10632042,bioavailabilities,"Furthermore 3-3 and 3-4 had superior bioavailabilities at these doses (59 and 46% (i.p.), respectively; 2 and 10%, (p.o.), respectively).",Structure-activity studies on 4-substituted-2-anilinopyrimidine corticotropin releasing factor (CRF) antagonists. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10632042/),%,46,20557,DB01285,Corticotropin
,10632042,bioavailabilities,"Furthermore 3-3 and 3-4 had superior bioavailabilities at these doses (59 and 46% (i.p.), respectively; 2 and 10%, (p.o.), respectively).",Structure-activity studies on 4-substituted-2-anilinopyrimidine corticotropin releasing factor (CRF) antagonists. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10632042/),%,2,20558,DB01285,Corticotropin
,10632042,bioavailabilities,"Furthermore 3-3 and 3-4 had superior bioavailabilities at these doses (59 and 46% (i.p.), respectively; 2 and 10%, (p.o.), respectively).",Structure-activity studies on 4-substituted-2-anilinopyrimidine corticotropin releasing factor (CRF) antagonists. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10632042/),%,10,20559,DB01285,Corticotropin
<,10072681,Ki's,Variations of amino (ether) pendants and aromatic substituents have defined the structure-activity relationships of these series and resulted in the identification of a variety of high-affinity agents (Ki's < 10 nM).,"Synthesis, corticotropin-releasing factor receptor binding affinity, and pharmacokinetic properties of triazolo-, imidazo-, and pyrrolopyrimidines and -pyridines. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10072681/),nM,10,21461,DB01285,Corticotropin
,8382708,apparent elimination half-life,The apparent elimination half-life at the higher doses was 3.7 hours.,"Evaluation of the pharmacokinetics and tolerability of tirilazad mesylate, a 21-aminosteroid free radical scavenger: I. Single-dose administration. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8382708/),h,3.7,27652,DB01285,Corticotropin
,8306072,nasal bioavailability,"2. Without additives the nasal bioavailability of the peptide was in the order of 15 and 10% in rats and rabbits, respectively.",Nasal administration of an ACTH(4-9) peptide analogue with dimethyl-beta-cyclodextrin as an absorption enhancer: pharmacokinetics and dynamics. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8306072/),%,15,29070,DB01285,Corticotropin
,8306072,nasal bioavailability,"2. Without additives the nasal bioavailability of the peptide was in the order of 15 and 10% in rats and rabbits, respectively.",Nasal administration of an ACTH(4-9) peptide analogue with dimethyl-beta-cyclodextrin as an absorption enhancer: pharmacokinetics and dynamics. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8306072/),%,10,29071,DB01285,Corticotropin
,33159976,time to maximum plasma concentration,"At steady state, ACT-539313 was rapidly absorbed with a median time to maximum plasma concentration of 1.8-2.3 h and eliminated with a mean half-life of 3.8-6.5 h.",Multiple-dose clinical pharmacology of the selective orexin-1 receptor antagonist ACT-539313. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33159976/),h,1.8-2.3,31779,DB01285,Corticotropin
,33159976,half-life,"At steady state, ACT-539313 was rapidly absorbed with a median time to maximum plasma concentration of 1.8-2.3 h and eliminated with a mean half-life of 3.8-6.5 h.",Multiple-dose clinical pharmacology of the selective orexin-1 receptor antagonist ACT-539313. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33159976/),h,3.8-6.5,31780,DB01285,Corticotropin
,12008748,peak,"However, the increment in plasma 17-OHP in patients both in terms of peak [13.76 +/- 2.52, 4.77 +/- 0.30ng/ml, mean +/- S.E.M, p < 0.001] and area under the curve [190 +/- 46, 96.75 +/- 32 ng/ml/h, p < 0.001] were significantly higher than that of the controls.",Twenty-four hour 17-hydroxyprogesterone response to adrenocorticotropine in adrenal incidentalomas: augmented response after adrenalectomy in two patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12008748/),[ng] / [ml],13.76,36625,DB01285,Corticotropin
,12008748,peak,"However, the increment in plasma 17-OHP in patients both in terms of peak [13.76 +/- 2.52, 4.77 +/- 0.30ng/ml, mean +/- S.E.M, p < 0.001] and area under the curve [190 +/- 46, 96.75 +/- 32 ng/ml/h, p < 0.001] were significantly higher than that of the controls.",Twenty-four hour 17-hydroxyprogesterone response to adrenocorticotropine in adrenal incidentalomas: augmented response after adrenalectomy in two patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12008748/),[ng] / [ml],4.77,36626,DB01285,Corticotropin
,12008748,area under the curve,"However, the increment in plasma 17-OHP in patients both in terms of peak [13.76 +/- 2.52, 4.77 +/- 0.30ng/ml, mean +/- S.E.M, p < 0.001] and area under the curve [190 +/- 46, 96.75 +/- 32 ng/ml/h, p < 0.001] were significantly higher than that of the controls.",Twenty-four hour 17-hydroxyprogesterone response to adrenocorticotropine in adrenal incidentalomas: augmented response after adrenalectomy in two patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12008748/),[ng] / [h·ml],190,36627,DB01285,Corticotropin
,12008748,area under the curve,"However, the increment in plasma 17-OHP in patients both in terms of peak [13.76 +/- 2.52, 4.77 +/- 0.30ng/ml, mean +/- S.E.M, p < 0.001] and area under the curve [190 +/- 46, 96.75 +/- 32 ng/ml/h, p < 0.001] were significantly higher than that of the controls.",Twenty-four hour 17-hydroxyprogesterone response to adrenocorticotropine in adrenal incidentalomas: augmented response after adrenalectomy in two patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12008748/),[ng] / [h·ml],96.75,36628,DB01285,Corticotropin
less,1649300,half-life,The half-life of alprazolam in rats is less than 1 h in both plasma and brain.,"The effects of alprazolam on corticotropin-releasing factor neurons in the rat brain: acute time course, chronic treatment and abrupt withdrawal. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1649300/),h,1,49991,DB01285,Corticotropin
,16712469,K(i),"For example, DMP696 has a K(i) value of 1.7 nM and a cLogP of 3.2, which is similar to CP-154,526 in potency but about 4-log units lower in partition coefficient.",Recent advances in small molecule antagonists of the corticotropin-releasing factor type-1 receptor-focus on pharmacology and pharmacokinetics. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16712469/),nM,1.7,50596,DB01285,Corticotropin
,16712469,cLogP,"For example, DMP696 has a K(i) value of 1.7 nM and a cLogP of 3.2, which is similar to CP-154,526 in potency but about 4-log units lower in partition coefficient.",Recent advances in small molecule antagonists of the corticotropin-releasing factor type-1 receptor-focus on pharmacology and pharmacokinetics. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16712469/),,3.2,50597,DB01285,Corticotropin
,16712469,plasma protein binding,"Despite its high plasma protein binding (98.5% in rat), DMP696 occupies over 50% of brain CRF(1)-R at a total plasma concentration above 100 nM, which is consistent with the doses that produce anxiolytic effects in the rat defense withdrawal test of anxiety.",Recent advances in small molecule antagonists of the corticotropin-releasing factor type-1 receptor-focus on pharmacology and pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16712469/),%,98.5,50598,DB01285,Corticotropin
,15179444,half-life,Its pharmacokinetic (PK) profile (half-life of 2 h) contrasts with the long lasting improvement in working memory (18 h) demonstrating that cognitive improvement extends beyond the lifetime of the compound.,"TC-1734: an orally active neuronal nicotinic acetylcholine receptor modulator with antidepressant, neuroprotective and long-lasting cognitive effects. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15179444/),h,2,53603,DB01285,Corticotropin
,12392842,half-lives,"Pharmacokinetics were similar in normal and HF sheep with half-lives approximating 1.3 and 19.5 h for the first and second phases, respectively.","Beneficial hemodynamic, endocrine, and renal effects of urocortin in experimental heart failure: comparison with normal sheep. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12392842/),h,1.3,55876,DB01285,Corticotropin
,12392842,half-lives,"Pharmacokinetics were similar in normal and HF sheep with half-lives approximating 1.3 and 19.5 h for the first and second phases, respectively.","Beneficial hemodynamic, endocrine, and renal effects of urocortin in experimental heart failure: comparison with normal sheep. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12392842/),h,19.5,55877,DB01285,Corticotropin
,24619932,terminal half-life,LY2456302 displayed rapid oral absorption and a terminal half-life of approximately 30-40 hours.,"Safety, tolerability, and pharmacokinetic evaluation of single- and multiple-ascending doses of a novel kappa opioid receptor antagonist LY2456302 and drug interaction with ethanol in healthy subjects. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24619932/),h,30-40,57236,DB01285,Corticotropin
,188965,maximal,Constant rate i.v. infusion of synthetic ACTH increased the plasma concentrations of both steroids to maximal values of 0-42 +/- 0-23 mug cortisol/100 ml and 1-06 +/- 0-56 mug corticosterone/100 ml at infusion rates of 1 i.u. ACTH/kg/h.,"Adrenocortical function in a prototherian mammal, Tachyglossus aculeatus (Shaw). ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/188965/),μg,0,59823,DB01285,Corticotropin
,188965,maximal,Constant rate i.v. infusion of synthetic ACTH increased the plasma concentrations of both steroids to maximal values of 0-42 +/- 0-23 mug cortisol/100 ml and 1-06 +/- 0-56 mug corticosterone/100 ml at infusion rates of 1 i.u. ACTH/kg/h.,"Adrenocortical function in a prototherian mammal, Tachyglossus aculeatus (Shaw). ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/188965/),μg,1-06,59824,DB01285,Corticotropin
,188965,production rates,"The production rates of corticosterone and cortisol, measured by isotope dilution during constant rate i.v. infusion of 3H-labelled tracers, were only 0-35 +/- 0-21 and 0-56 +/- 0-26 mug/kg/h respectively during saline infusion, and increased to 2-86 +/- 3-47 and 2-74 +/- 2-07 mug/kg/h during the infusion of 1 i.u. ACTH/kg/h.","Adrenocortical function in a prototherian mammal, Tachyglossus aculeatus (Shaw). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/188965/),[μg] / [h·kg],0-35,59825,DB01285,Corticotropin
,188965,production rates,"The production rates of corticosterone and cortisol, measured by isotope dilution during constant rate i.v. infusion of 3H-labelled tracers, were only 0-35 +/- 0-21 and 0-56 +/- 0-26 mug/kg/h respectively during saline infusion, and increased to 2-86 +/- 3-47 and 2-74 +/- 2-07 mug/kg/h during the infusion of 1 i.u. ACTH/kg/h.","Adrenocortical function in a prototherian mammal, Tachyglossus aculeatus (Shaw). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/188965/),[μg] / [h·kg],0,59826,DB01285,Corticotropin
,188965,production rates,"The production rates of corticosterone and cortisol, measured by isotope dilution during constant rate i.v. infusion of 3H-labelled tracers, were only 0-35 +/- 0-21 and 0-56 +/- 0-26 mug/kg/h respectively during saline infusion, and increased to 2-86 +/- 3-47 and 2-74 +/- 2-07 mug/kg/h during the infusion of 1 i.u. ACTH/kg/h.","Adrenocortical function in a prototherian mammal, Tachyglossus aculeatus (Shaw). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/188965/),[μg] / [h·kg],2-86,59827,DB01285,Corticotropin
,188965,production rates,"The production rates of corticosterone and cortisol, measured by isotope dilution during constant rate i.v. infusion of 3H-labelled tracers, were only 0-35 +/- 0-21 and 0-56 +/- 0-26 mug/kg/h respectively during saline infusion, and increased to 2-86 +/- 3-47 and 2-74 +/- 2-07 mug/kg/h during the infusion of 1 i.u. ACTH/kg/h.","Adrenocortical function in a prototherian mammal, Tachyglossus aculeatus (Shaw). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/188965/),[μg] / [h·kg],2-74,59828,DB01285,Corticotropin
,29385232,plasma half-life,"2B3-201 was shown to have a plasma half-life between 24 and 37 h and caused a prolonged decrease in the lymphocyte count, adrenocorticotropic hormone and osteocalcin, and a rise in fasting glucose.",Glutathione-PEGylated liposomal methylprednisolone in comparison to free methylprednisolone: slow release characteristics and prolonged lymphocyte depression in a first-in-human study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29385232/),h,24 and 37,61204,DB01285,Corticotropin
,16353581,area under the curve AUC,The area under the curve AUC for ACTH after clomipramine was 6202 +/- 976 pg/ml x 150 minutes for tile obese before weight loss and 3274 +/- 512 pg/ml x 150 minutes for the controls and the difference was significant at the level of p=0.052.,Hypersensitivity of the corticotropic axis to the serotoninergic agent clomipramine in obese women. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16353581/),[pg] / [150·min·ml],6202,62335,DB01285,Corticotropin
,16353581,area under the curve AUC,The area under the curve AUC for ACTH after clomipramine was 6202 +/- 976 pg/ml x 150 minutes for tile obese before weight loss and 3274 +/- 512 pg/ml x 150 minutes for the controls and the difference was significant at the level of p=0.052.,Hypersensitivity of the corticotropic axis to the serotoninergic agent clomipramine in obese women. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16353581/),[pg] / [150·min·ml],3274,62336,DB01285,Corticotropin
,16353581,peak value,The cortisol peak value after clomipramine was 163.71 +/- 14.31 ng/ml in the non-obese and 214.66 +/- 12.59 ng/ml in the obese (p=0.025).,Hypersensitivity of the corticotropic axis to the serotoninergic agent clomipramine in obese women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16353581/),[ng] / [ml],163.71,62337,DB01285,Corticotropin
,16353581,peak value,The cortisol peak value after clomipramine was 163.71 +/- 14.31 ng/ml in the non-obese and 214.66 +/- 12.59 ng/ml in the obese (p=0.025).,Hypersensitivity of the corticotropic axis to the serotoninergic agent clomipramine in obese women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16353581/),[ng] / [ml],214.66,62338,DB01285,Corticotropin
,28012176,terminal t1/2,"Following multiple doses of UE2343, plasma levels were approximately dose proportional and the terminal t1/2 ranged from 10 to 14 h.",Selection and early clinical evaluation of the brain-penetrant 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor UE2343 (Xanamem™). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28012176/),h,10 to 14,68583,DB01285,Corticotropin
,11792687,first half-life,"After i.v. bolus, the concentration declined in a biphasic manner, the first half-life being 0.9 h and the terminal one being 51 h.",Brain pharmacokinetics of a nonpeptidic corticotropin-releasing factor receptor antagonist. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11792687/),h,0.9,71440,DB01285,Corticotropin
,11792687,terminal,"After i.v. bolus, the concentration declined in a biphasic manner, the first half-life being 0.9 h and the terminal one being 51 h.",Brain pharmacokinetics of a nonpeptidic corticotropin-releasing factor receptor antagonist. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11792687/),h,51,71441,DB01285,Corticotropin
,11792687,Systemic clearance,"Systemic clearance was 36 ml/min/kg, and the volume of distribution was 105 l/kg.",Brain pharmacokinetics of a nonpeptidic corticotropin-releasing factor receptor antagonist. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11792687/),[ml] / [kg·min],36,71442,DB01285,Corticotropin
,11792687,volume of distribution,"Systemic clearance was 36 ml/min/kg, and the volume of distribution was 105 l/kg.",Brain pharmacokinetics of a nonpeptidic corticotropin-releasing factor receptor antagonist. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11792687/),[l] / [kg],105,71443,DB01285,Corticotropin
,11792687,Oral bioavailability,Oral bioavailability reached 27%.,Brain pharmacokinetics of a nonpeptidic corticotropin-releasing factor receptor antagonist. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11792687/),%,27,71444,DB01285,Corticotropin
,11792687,brain extraction ratio,"The unidirectional brain extraction ratio was 27 and 9% at vascular concentrations of 0.08 and 16 nmol/ml, respectively.",Brain pharmacokinetics of a nonpeptidic corticotropin-releasing factor receptor antagonist. ,E-Q38,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11792687/),%,27,71445,DB01285,Corticotropin
,11792687,brain extraction ratio,"The unidirectional brain extraction ratio was 27 and 9% at vascular concentrations of 0.08 and 16 nmol/ml, respectively.",Brain pharmacokinetics of a nonpeptidic corticotropin-releasing factor receptor antagonist. ,E-Q38,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11792687/),%,9,71446,DB01285,Corticotropin
,17088419,tmax,"Kinetic analysis of both the preparations demonstrated rapid absorption (tmax, 0.6-1.5 h) and low maximum plasma concentrations (peak Cmax, 2.99-5.51 nmol/l) of the steroids; indeed, the terminal half-life of TAA-DHP (13.9 +/- 1.3 h) was very much shorter than that of TAA (125.9 +/- 15.8 h).",Comparison of the hypothalamic-pituitary-adrenal axis susceptibility upon single-dose i.m. depot versus long-acting i.v. triamcinolone acetonide therapy: a direct pharmacokinetic correlation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17088419/),h,0.6-1.5,72211,DB01285,Corticotropin
,17088419,maximum,"Kinetic analysis of both the preparations demonstrated rapid absorption (tmax, 0.6-1.5 h) and low maximum plasma concentrations (peak Cmax, 2.99-5.51 nmol/l) of the steroids; indeed, the terminal half-life of TAA-DHP (13.9 +/- 1.3 h) was very much shorter than that of TAA (125.9 +/- 15.8 h).",Comparison of the hypothalamic-pituitary-adrenal axis susceptibility upon single-dose i.m. depot versus long-acting i.v. triamcinolone acetonide therapy: a direct pharmacokinetic correlation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17088419/),[nM] / [l],2.99-5.51,72212,DB01285,Corticotropin
,17088419,terminal half-life,"Kinetic analysis of both the preparations demonstrated rapid absorption (tmax, 0.6-1.5 h) and low maximum plasma concentrations (peak Cmax, 2.99-5.51 nmol/l) of the steroids; indeed, the terminal half-life of TAA-DHP (13.9 +/- 1.3 h) was very much shorter than that of TAA (125.9 +/- 15.8 h).",Comparison of the hypothalamic-pituitary-adrenal axis susceptibility upon single-dose i.m. depot versus long-acting i.v. triamcinolone acetonide therapy: a direct pharmacokinetic correlation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17088419/),h,13.9,72213,DB01285,Corticotropin
,17088419,terminal half-life,"Kinetic analysis of both the preparations demonstrated rapid absorption (tmax, 0.6-1.5 h) and low maximum plasma concentrations (peak Cmax, 2.99-5.51 nmol/l) of the steroids; indeed, the terminal half-life of TAA-DHP (13.9 +/- 1.3 h) was very much shorter than that of TAA (125.9 +/- 15.8 h).",Comparison of the hypothalamic-pituitary-adrenal axis susceptibility upon single-dose i.m. depot versus long-acting i.v. triamcinolone acetonide therapy: a direct pharmacokinetic correlation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17088419/),h,125.9,72214,DB01285,Corticotropin
,17088419,mean residence time,"In addition, the mean residence time differed very much (11 vs 160 h for TAA-DHP and TAA respectively), in line with a delayed elimination of the depot compared with the long-acting formulation.",Comparison of the hypothalamic-pituitary-adrenal axis susceptibility upon single-dose i.m. depot versus long-acting i.v. triamcinolone acetonide therapy: a direct pharmacokinetic correlation. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17088419/),h,11,72215,DB01285,Corticotropin
,17088419,mean residence time,"In addition, the mean residence time differed very much (11 vs 160 h for TAA-DHP and TAA respectively), in line with a delayed elimination of the depot compared with the long-acting formulation.",Comparison of the hypothalamic-pituitary-adrenal axis susceptibility upon single-dose i.m. depot versus long-acting i.v. triamcinolone acetonide therapy: a direct pharmacokinetic correlation. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17088419/),h,160,72216,DB01285,Corticotropin
less,29459145,IC50,"The synthesized tricyclic derivatives 2a-e showed CRF1 receptor binding activity with IC50 values of less than 400 nM, and the 1,2,3,4-tetrahydropyrimido-[1,2-a]benzimidazole derivative 2e was selected as a lead compound with potent in vitro CRF1 receptor binding activity (IC50 = 7.1 nM).","Discovery of 1,2,3,4-tetrahydropyrimido[1,2-a]benzimidazoles as novel class of corticotropin releasing factor 1 receptor antagonists. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29459145/),nM,400,74586,DB01285,Corticotropin
,29459145,IC50,"The synthesized tricyclic derivatives 2a-e showed CRF1 receptor binding activity with IC50 values of less than 400 nM, and the 1,2,3,4-tetrahydropyrimido-[1,2-a]benzimidazole derivative 2e was selected as a lead compound with potent in vitro CRF1 receptor binding activity (IC50 = 7.1 nM).","Discovery of 1,2,3,4-tetrahydropyrimido[1,2-a]benzimidazoles as novel class of corticotropin releasing factor 1 receptor antagonists. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29459145/),nM,7.1,74587,DB01285,Corticotropin
,29459145,IC50,"To optimize the pharmacokinetic profiles of lead compound 2e, we explored suitable substituents on the 1-position and 6-position, leading to the identification of compound 42c-R, which exhibited potent CRF1 receptor binding activity (IC50 = 58 nM) with good oral bioavailability (F = 68% in rats).","Discovery of 1,2,3,4-tetrahydropyrimido[1,2-a]benzimidazoles as novel class of corticotropin releasing factor 1 receptor antagonists. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29459145/),nM,58,74588,DB01285,Corticotropin
,29459145,oral bioavailability (F,"To optimize the pharmacokinetic profiles of lead compound 2e, we explored suitable substituents on the 1-position and 6-position, leading to the identification of compound 42c-R, which exhibited potent CRF1 receptor binding activity (IC50 = 58 nM) with good oral bioavailability (F = 68% in rats).","Discovery of 1,2,3,4-tetrahydropyrimido[1,2-a]benzimidazoles as novel class of corticotropin releasing factor 1 receptor antagonists. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29459145/),%,68,74589,DB01285,Corticotropin
,6092407,MCR,The difference in duration of effect between hCRF and oCRF may be attributed to an approximately 3-4 times higher MCR of hCRF [7.9 +/- 1.2 (+/- SE) ml/kg min; n = 14] than oCRF (1.9 +/- 0.1 ml/kg min; n = 9) in man.,Human corticotropin-releasing factor in man: pharmacokinetic properties and dose-response of plasma adrenocorticotropin and cortisol secretion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6092407/),[ml] / [kg·min],7.9,82497,DB01285,Corticotropin
,6092407,MCR,The difference in duration of effect between hCRF and oCRF may be attributed to an approximately 3-4 times higher MCR of hCRF [7.9 +/- 1.2 (+/- SE) ml/kg min; n = 14] than oCRF (1.9 +/- 0.1 ml/kg min; n = 9) in man.,Human corticotropin-releasing factor in man: pharmacokinetic properties and dose-response of plasma adrenocorticotropin and cortisol secretion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6092407/),[ml] / [kg·min],1.9,82498,DB01285,Corticotropin
,10968277,Ki,"Compound 11-31 (hCRF1 Ki = 1.0+/-0.2 nM (n = 8)) was a potent antagonist of hCRF1-coupled adenylate cyclase activity in HEK293 cells (IC50= 10.0+/-0.01 nM versus 10 nM r/hCRF, n = 8); alpha-helical CRF(9-41) had weaker potency (IC50 = 286+/-63 nM, n = 3).","The discovery of 4-(3-pentylamino)-2,7-dimethyl-8-(2-methyl-4-methoxyphenyl)-pyrazolo-[1 ,5-a]-pyrimidine: a corticotropin-releasing factor (hCRF1) antagonist. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10968277/),nM,1.0,85651,DB01285,Corticotropin
,10968277,IC50,"Compound 11-31 (hCRF1 Ki = 1.0+/-0.2 nM (n = 8)) was a potent antagonist of hCRF1-coupled adenylate cyclase activity in HEK293 cells (IC50= 10.0+/-0.01 nM versus 10 nM r/hCRF, n = 8); alpha-helical CRF(9-41) had weaker potency (IC50 = 286+/-63 nM, n = 3).","The discovery of 4-(3-pentylamino)-2,7-dimethyl-8-(2-methyl-4-methoxyphenyl)-pyrazolo-[1 ,5-a]-pyrimidine: a corticotropin-releasing factor (hCRF1) antagonist. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10968277/),nM,10.0,85652,DB01285,Corticotropin
,10968277,IC50,"Compound 11-31 (hCRF1 Ki = 1.0+/-0.2 nM (n = 8)) was a potent antagonist of hCRF1-coupled adenylate cyclase activity in HEK293 cells (IC50= 10.0+/-0.01 nM versus 10 nM r/hCRF, n = 8); alpha-helical CRF(9-41) had weaker potency (IC50 = 286+/-63 nM, n = 3).","The discovery of 4-(3-pentylamino)-2,7-dimethyl-8-(2-methyl-4-methoxyphenyl)-pyrazolo-[1 ,5-a]-pyrimidine: a corticotropin-releasing factor (hCRF1) antagonist. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10968277/),[nM·r] / [hcrf],10,85653,DB01285,Corticotropin
,10968277,IC50,"Compound 11-31 (hCRF1 Ki = 1.0+/-0.2 nM (n = 8)) was a potent antagonist of hCRF1-coupled adenylate cyclase activity in HEK293 cells (IC50= 10.0+/-0.01 nM versus 10 nM r/hCRF, n = 8); alpha-helical CRF(9-41) had weaker potency (IC50 = 286+/-63 nM, n = 3).","The discovery of 4-(3-pentylamino)-2,7-dimethyl-8-(2-methyl-4-methoxyphenyl)-pyrazolo-[1 ,5-a]-pyrimidine: a corticotropin-releasing factor (hCRF1) antagonist. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10968277/),nM,286,85654,DB01285,Corticotropin
,10968277,minimum effective dose,Analogue 11-31 had good oral activity in the rat situational anxiety test; the minimum effective dose for 11-31 was 0.3 mg/kg (po).,"The discovery of 4-(3-pentylamino)-2,7-dimethyl-8-(2-methyl-4-methoxyphenyl)-pyrazolo-[1 ,5-a]-pyrimidine: a corticotropin-releasing factor (hCRF1) antagonist. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10968277/),[mg] / [kg],0.3,85655,DB01285,Corticotropin
,10968277,t1/2,"The key iv pharmacokinetic parameters were t1/2, CL and Vd,ss values equal to 46.4+/-7.6 h. 0.49+/-0.08 L/kg/h and 23.0+/-4.2 L/kg, respectively.","The discovery of 4-(3-pentylamino)-2,7-dimethyl-8-(2-methyl-4-methoxyphenyl)-pyrazolo-[1 ,5-a]-pyrimidine: a corticotropin-releasing factor (hCRF1) antagonist. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10968277/),h,46.4,85656,DB01285,Corticotropin
,10968277,CL,"The key iv pharmacokinetic parameters were t1/2, CL and Vd,ss values equal to 46.4+/-7.6 h. 0.49+/-0.08 L/kg/h and 23.0+/-4.2 L/kg, respectively.","The discovery of 4-(3-pentylamino)-2,7-dimethyl-8-(2-methyl-4-methoxyphenyl)-pyrazolo-[1 ,5-a]-pyrimidine: a corticotropin-releasing factor (hCRF1) antagonist. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10968277/),[l] / [h·kg],0.49,85657,DB01285,Corticotropin
,10968277,"Vd,ss","The key iv pharmacokinetic parameters were t1/2, CL and Vd,ss values equal to 46.4+/-7.6 h. 0.49+/-0.08 L/kg/h and 23.0+/-4.2 L/kg, respectively.","The discovery of 4-(3-pentylamino)-2,7-dimethyl-8-(2-methyl-4-methoxyphenyl)-pyrazolo-[1 ,5-a]-pyrimidine: a corticotropin-releasing factor (hCRF1) antagonist. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10968277/),[l] / [kg],23.0,85658,DB01285,Corticotropin
,10968277,Cmax,"After oral dosing, the mean Cmax, Tmax t1/2 and bioavailability values were equal to 1260+/-290 nM, 0.75+/-0.25 h. 45.1+/-10.2 h and 33.1%, respectively.","The discovery of 4-(3-pentylamino)-2,7-dimethyl-8-(2-methyl-4-methoxyphenyl)-pyrazolo-[1 ,5-a]-pyrimidine: a corticotropin-releasing factor (hCRF1) antagonist. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10968277/),nM,1260,85659,DB01285,Corticotropin
,10968277,Tmax t1/2,"After oral dosing, the mean Cmax, Tmax t1/2 and bioavailability values were equal to 1260+/-290 nM, 0.75+/-0.25 h. 45.1+/-10.2 h and 33.1%, respectively.","The discovery of 4-(3-pentylamino)-2,7-dimethyl-8-(2-methyl-4-methoxyphenyl)-pyrazolo-[1 ,5-a]-pyrimidine: a corticotropin-releasing factor (hCRF1) antagonist. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10968277/),h,0.75,85660,DB01285,Corticotropin
,10968277,Tmax t1/2,"After oral dosing, the mean Cmax, Tmax t1/2 and bioavailability values were equal to 1260+/-290 nM, 0.75+/-0.25 h. 45.1+/-10.2 h and 33.1%, respectively.","The discovery of 4-(3-pentylamino)-2,7-dimethyl-8-(2-methyl-4-methoxyphenyl)-pyrazolo-[1 ,5-a]-pyrimidine: a corticotropin-releasing factor (hCRF1) antagonist. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10968277/),h,45.1,85661,DB01285,Corticotropin
,10968277,bioavailability,"After oral dosing, the mean Cmax, Tmax t1/2 and bioavailability values were equal to 1260+/-290 nM, 0.75+/-0.25 h. 45.1+/-10.2 h and 33.1%, respectively.","The discovery of 4-(3-pentylamino)-2,7-dimethyl-8-(2-methyl-4-methoxyphenyl)-pyrazolo-[1 ,5-a]-pyrimidine: a corticotropin-releasing factor (hCRF1) antagonist. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10968277/),%,33.1,85662,DB01285,Corticotropin
,15509177,IC50,"Members within a series of 3,4-dihydro-1H-pyrido[2,3-b]pyrazin-2-ones, exemplified by compound 2 (IC50 = 0.70 nM), were found to be very potent antagonists of CRF1.","Synthesis, structure-activity relationships, and in vivo properties of 3,4-dihydro-1H-pyrido[2,3-b]pyrazin-2-ones as corticotropin-releasing factor-1 receptor antagonists. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15509177/),nM,0.70,88651,DB01285,Corticotropin
,10669572,K(i),"Structure-activity studies in the pyrazolo[1,5-a]-1,3,5-triazine series led to the discovery that compound 11i (DMP696) is a potent hCRF(1) receptor antagonist (K(i) = 1.7 nM vs 7.5 nM for alpha-hel-CRF(9-41), hCRF(1) adenylate cyclase IC(50) = 82 nM vs 286 nM for alpha-hel-CRF(9-41)).","4-(1,3-Dimethoxyprop-2-ylamino)-2,7-dimethyl-8-(2, 4-dichlorophenyl)pyrazolo[1,5-a]-1,3,5-triazine: a potent, orally bioavailable CRF(1) receptor antagonist. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10669572/),nM,1.7,89867,DB01285,Corticotropin
,10669572,K(i),"Structure-activity studies in the pyrazolo[1,5-a]-1,3,5-triazine series led to the discovery that compound 11i (DMP696) is a potent hCRF(1) receptor antagonist (K(i) = 1.7 nM vs 7.5 nM for alpha-hel-CRF(9-41), hCRF(1) adenylate cyclase IC(50) = 82 nM vs 286 nM for alpha-hel-CRF(9-41)).","4-(1,3-Dimethoxyprop-2-ylamino)-2,7-dimethyl-8-(2, 4-dichlorophenyl)pyrazolo[1,5-a]-1,3,5-triazine: a potent, orally bioavailable CRF(1) receptor antagonist. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10669572/),nM,7.5,89868,DB01285,Corticotropin
,10669572,IC(50),"Structure-activity studies in the pyrazolo[1,5-a]-1,3,5-triazine series led to the discovery that compound 11i (DMP696) is a potent hCRF(1) receptor antagonist (K(i) = 1.7 nM vs 7.5 nM for alpha-hel-CRF(9-41), hCRF(1) adenylate cyclase IC(50) = 82 nM vs 286 nM for alpha-hel-CRF(9-41)).","4-(1,3-Dimethoxyprop-2-ylamino)-2,7-dimethyl-8-(2, 4-dichlorophenyl)pyrazolo[1,5-a]-1,3,5-triazine: a potent, orally bioavailable CRF(1) receptor antagonist. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10669572/),nM,82,89869,DB01285,Corticotropin
,10669572,IC(50),"Structure-activity studies in the pyrazolo[1,5-a]-1,3,5-triazine series led to the discovery that compound 11i (DMP696) is a potent hCRF(1) receptor antagonist (K(i) = 1.7 nM vs 7.5 nM for alpha-hel-CRF(9-41), hCRF(1) adenylate cyclase IC(50) = 82 nM vs 286 nM for alpha-hel-CRF(9-41)).","4-(1,3-Dimethoxyprop-2-ylamino)-2,7-dimethyl-8-(2, 4-dichlorophenyl)pyrazolo[1,5-a]-1,3,5-triazine: a potent, orally bioavailable CRF(1) receptor antagonist. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10669572/),nM,286,89870,DB01285,Corticotropin
,10669572,oral bioavailabilities,"Compound 11i has excellent oral pharmacokinetic profiles in rats and dogs (37% and 50% oral bioavailabilities, respectively).","4-(1,3-Dimethoxyprop-2-ylamino)-2,7-dimethyl-8-(2, 4-dichlorophenyl)pyrazolo[1,5-a]-1,3,5-triazine: a potent, orally bioavailable CRF(1) receptor antagonist. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10669572/),%,37,89871,DB01285,Corticotropin
,10669572,oral bioavailabilities,"Compound 11i has excellent oral pharmacokinetic profiles in rats and dogs (37% and 50% oral bioavailabilities, respectively).","4-(1,3-Dimethoxyprop-2-ylamino)-2,7-dimethyl-8-(2, 4-dichlorophenyl)pyrazolo[1,5-a]-1,3,5-triazine: a potent, orally bioavailable CRF(1) receptor antagonist. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10669572/),%,50,89872,DB01285,Corticotropin
,31082785,Maximum plasma concentrations,Maximum plasma concentrations after the first oral dose of pergolide (0.104-0.684 ng/mL; median 0.261 ng/mL; interquartile range [IQR] 0.184-0.416 ng/mL) were not significantly different to the maximum steady-state concentration at day 18 (0.197-0.628 ng/mL; median 0.274; IQR 0.232-0.458 ng/mL).,Pharmacokinetics and pharmacodynamics of pergolide mesylate after oral administration in horses with pituitary pars intermedia dysfunction. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31082785/),[ng] / [ml],0.104-0.684,91667,DB01285,Corticotropin
,31082785,Maximum plasma concentrations,Maximum plasma concentrations after the first oral dose of pergolide (0.104-0.684 ng/mL; median 0.261 ng/mL; interquartile range [IQR] 0.184-0.416 ng/mL) were not significantly different to the maximum steady-state concentration at day 18 (0.197-0.628 ng/mL; median 0.274; IQR 0.232-0.458 ng/mL).,Pharmacokinetics and pharmacodynamics of pergolide mesylate after oral administration in horses with pituitary pars intermedia dysfunction. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31082785/),[ng] / [ml],0.261,91668,DB01285,Corticotropin
,31082785,maximum steady-state concentration,Maximum plasma concentrations after the first oral dose of pergolide (0.104-0.684 ng/mL; median 0.261 ng/mL; interquartile range [IQR] 0.184-0.416 ng/mL) were not significantly different to the maximum steady-state concentration at day 18 (0.197-0.628 ng/mL; median 0.274; IQR 0.232-0.458 ng/mL).,Pharmacokinetics and pharmacodynamics of pergolide mesylate after oral administration in horses with pituitary pars intermedia dysfunction. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31082785/),[ng] / [ml],0.274,91669,DB01285,Corticotropin
less,31082785,terminal elimination half-life,Fluctuations in pergolide concentration were consistent with a terminal elimination half-life of less than 12 h.,Pharmacokinetics and pharmacodynamics of pergolide mesylate after oral administration in horses with pituitary pars intermedia dysfunction. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/31082785/),h,12,91670,DB01285,Corticotropin
,17344409,ED50,"After oral administration to rats, MTIP inhibited 125I-sauvagine binding to rat cerebellar membranes ex vivo with an ED50 of approximately 1.3 mg/kg and an oral bioavailability of 91.1%.","3-(4-Chloro-2-morpholin-4-yl-thiazol-5-yl)-8-(1-ethylpropyl)-2,6-dimethyl-imidazo[1,2-b]pyridazine: a novel brain-penetrant, orally available corticotropin-releasing factor receptor 1 antagonist with efficacy in animal models of alcoholism. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17344409/),[mg] / [kg],1.3,92788,DB01285,Corticotropin
,17344409,oral bioavailability,"After oral administration to rats, MTIP inhibited 125I-sauvagine binding to rat cerebellar membranes ex vivo with an ED50 of approximately 1.3 mg/kg and an oral bioavailability of 91.1%.","3-(4-Chloro-2-morpholin-4-yl-thiazol-5-yl)-8-(1-ethylpropyl)-2,6-dimethyl-imidazo[1,2-b]pyridazine: a novel brain-penetrant, orally available corticotropin-releasing factor receptor 1 antagonist with efficacy in animal models of alcoholism. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17344409/),%,91.1,92789,DB01285,Corticotropin
,11115437,Plasma levels,"Study 2. Plasma levels over days 7 to 28 were 100.3 +/- 5.9 pg/mL (mean +/- SEM) for MF DPI 400 microg bid, and 181.0 +/- 10.9 pg/mL for 800 microg bid.",Mometasone furoate has minimal effects on the hypothalamic-pituitary-adrenal axis when delivered at high doses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11115437/),[pg] / [ml],100.3,95830,DB01285,Corticotropin
,11115437,Plasma levels,"Study 2. Plasma levels over days 7 to 28 were 100.3 +/- 5.9 pg/mL (mean +/- SEM) for MF DPI 400 microg bid, and 181.0 +/- 10.9 pg/mL for 800 microg bid.",Mometasone furoate has minimal effects on the hypothalamic-pituitary-adrenal axis when delivered at high doses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11115437/),[pg] / [ml],181.0,95831,DB01285,Corticotropin
,6288752,Plasma half-life,"Plasma half-life of I125-CRF was 17.1 +/- 2.44 min (mean +/- SE, n=4) for the fast component and 198 +/- 5.3 min for the slow component.",Metabolic clearance rate and plasma half-life of radioiodinated corticotropin releasing factor in a primate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6288752/),min,17.1,98594,DB01285,Corticotropin
,6288752,Plasma half-life,"Plasma half-life of I125-CRF was 17.1 +/- 2.44 min (mean +/- SE, n=4) for the fast component and 198 +/- 5.3 min for the slow component.",Metabolic clearance rate and plasma half-life of radioiodinated corticotropin releasing factor in a primate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6288752/),min,198,98595,DB01285,Corticotropin
,6288752,MCR,"The MCR of I125-CRF using the pulse injection technique was 0.44 +/- 0.06 L/Kg/d, n=4 and the volume of distribution 213.5 +/- 12 ml, n=4, roughly equal to the plasma volume.",Metabolic clearance rate and plasma half-life of radioiodinated corticotropin releasing factor in a primate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6288752/),[l] / [d·kg],0.44,98596,DB01285,Corticotropin
,6288752,volume of distribution,"The MCR of I125-CRF using the pulse injection technique was 0.44 +/- 0.06 L/Kg/d, n=4 and the volume of distribution 213.5 +/- 12 ml, n=4, roughly equal to the plasma volume.",Metabolic clearance rate and plasma half-life of radioiodinated corticotropin releasing factor in a primate. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6288752/),ml,213.5,98597,DB01285,Corticotropin
,6288752,MCR's,"Continuous infusion of I125-CRF and of I125-Tyro-CRF gave MCR's ranging between 2.23 -= 5.08 L/Kg/d, n=4.",Metabolic clearance rate and plasma half-life of radioiodinated corticotropin releasing factor in a primate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6288752/),[l] / [d·kg],2.23 -= 5.08,98598,DB01285,Corticotropin
,19954247,IC(50),"Further optimization of the structure-activity relationships and in vivo properties of pyrazinone-based CRF(1) receptor antagonists and studies to assess the formation of reactive metabolites led to the discovery of 19e, a high affinity CRF(1) receptor antagonist (IC(50) = 0.86 nM) wherein GSH adducts were estimated to be only 0.1% of the total amount of drug-related material excreted through bile and urine, indicating low levels of reactive metabolite formation in vivo.","A strategy to minimize reactive metabolite formation: discovery of (S)-4-(1-cyclopropyl-2-methoxyethyl)-6-[6-(difluoromethoxy)-2,5-dimethylpyridin-3-ylamino]-5-oxo-4,5-dihydropyrazine-2-carbonitrile as a potent, orally bioavailable corticotropin-releasing factor-1 receptor antagonist. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19954247/),nM,0.86,100099,DB01285,Corticotropin
,6607138,metabolic clearance rate,"The metabolic clearance rate, the apparent initial volume of distribution, the plasma half-life for the fast component and that for the slow component calculated from all eight tests in the morning and evening were 1.49 +/- 0.05 ml/min X kg, 44.4 +/- 1.7 ml/kg, 6.8 +/- 0.7 min and 46.2 +/- 2.3 min (mean +/- SEM), respectively.",Plasma disappearance of ovine corticotrophin-releasing factor in man. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6607138/),[ml] / [kg·min],1.49,102802,DB01285,Corticotropin
,6607138,apparent initial volume of distribution,"The metabolic clearance rate, the apparent initial volume of distribution, the plasma half-life for the fast component and that for the slow component calculated from all eight tests in the morning and evening were 1.49 +/- 0.05 ml/min X kg, 44.4 +/- 1.7 ml/kg, 6.8 +/- 0.7 min and 46.2 +/- 2.3 min (mean +/- SEM), respectively.",Plasma disappearance of ovine corticotrophin-releasing factor in man. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6607138/),[ml] / [kg],44.4,102803,DB01285,Corticotropin
,6607138,apparent initial volume of distribution,"The metabolic clearance rate, the apparent initial volume of distribution, the plasma half-life for the fast component and that for the slow component calculated from all eight tests in the morning and evening were 1.49 +/- 0.05 ml/min X kg, 44.4 +/- 1.7 ml/kg, 6.8 +/- 0.7 min and 46.2 +/- 2.3 min (mean +/- SEM), respectively.",Plasma disappearance of ovine corticotrophin-releasing factor in man. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6607138/),min,6.8,102804,DB01285,Corticotropin
,6607138,plasma half-life,"The metabolic clearance rate, the apparent initial volume of distribution, the plasma half-life for the fast component and that for the slow component calculated from all eight tests in the morning and evening were 1.49 +/- 0.05 ml/min X kg, 44.4 +/- 1.7 ml/kg, 6.8 +/- 0.7 min and 46.2 +/- 2.3 min (mean +/- SEM), respectively.",Plasma disappearance of ovine corticotrophin-releasing factor in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6607138/),min,46.2,102805,DB01285,Corticotropin
,15467976,absolute bioavailability,The absolute bioavailability ranged from 12% to 84%.,Pharmacokinetics of m-chlorophenylpiperazine after intravenous and oral administration in healthy male volunteers: implication for the pharmacodynamic profile. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15467976/),%,12,104832,DB01285,Corticotropin
,15467976,absolute bioavailability,The absolute bioavailability ranged from 12% to 84%.,Pharmacokinetics of m-chlorophenylpiperazine after intravenous and oral administration in healthy male volunteers: implication for the pharmacodynamic profile. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15467976/),%,84,104833,DB01285,Corticotropin
,15467976,elimination half-life,mCPP's elimination half-life ranged from 2.4 h to 6.8 h after intravenous infusion and from 2.6 h to 6.1 h after oral application.,Pharmacokinetics of m-chlorophenylpiperazine after intravenous and oral administration in healthy male volunteers: implication for the pharmacodynamic profile. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15467976/),h,2.4,104834,DB01285,Corticotropin
,15467976,elimination half-life,mCPP's elimination half-life ranged from 2.4 h to 6.8 h after intravenous infusion and from 2.6 h to 6.1 h after oral application.,Pharmacokinetics of m-chlorophenylpiperazine after intravenous and oral administration in healthy male volunteers: implication for the pharmacodynamic profile. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15467976/),h,6.8,104835,DB01285,Corticotropin
,15467976,elimination half-life,mCPP's elimination half-life ranged from 2.4 h to 6.8 h after intravenous infusion and from 2.6 h to 6.1 h after oral application.,Pharmacokinetics of m-chlorophenylpiperazine after intravenous and oral administration in healthy male volunteers: implication for the pharmacodynamic profile. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15467976/),h,2.6,104836,DB01285,Corticotropin
,15467976,elimination half-life,mCPP's elimination half-life ranged from 2.4 h to 6.8 h after intravenous infusion and from 2.6 h to 6.1 h after oral application.,Pharmacokinetics of m-chlorophenylpiperazine after intravenous and oral administration in healthy male volunteers: implication for the pharmacodynamic profile. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15467976/),h,6.1,104837,DB01285,Corticotropin
,19223520,peak,"The key variables in the physiological cortisol profile included: peak 15.5 microg/dl (95% reference range 11.7-20.6), acrophase 0832 h (95% confidence interval 0759-0905), nadir less than 2 microg/dl (95% reference range 1.5-2.5), time of nadir 0018 h (95% confidence interval 2339-0058), and quiescent phase (below the mesor) 1943-0531 h.",Modified-release hydrocortisone to provide circadian cortisol profiles. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19223520/),[μg] / [dl],15.5,115674,DB01285,Corticotropin
,19223520,acrophase,"The key variables in the physiological cortisol profile included: peak 15.5 microg/dl (95% reference range 11.7-20.6), acrophase 0832 h (95% confidence interval 0759-0905), nadir less than 2 microg/dl (95% reference range 1.5-2.5), time of nadir 0018 h (95% confidence interval 2339-0058), and quiescent phase (below the mesor) 1943-0531 h.",Modified-release hydrocortisone to provide circadian cortisol profiles. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19223520/),h,0832,115675,DB01285,Corticotropin
less,19223520,nadir,"The key variables in the physiological cortisol profile included: peak 15.5 microg/dl (95% reference range 11.7-20.6), acrophase 0832 h (95% confidence interval 0759-0905), nadir less than 2 microg/dl (95% reference range 1.5-2.5), time of nadir 0018 h (95% confidence interval 2339-0058), and quiescent phase (below the mesor) 1943-0531 h.",Modified-release hydrocortisone to provide circadian cortisol profiles. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19223520/),[μg] / [dl],2,115676,DB01285,Corticotropin
,19223520,time of nadir,"The key variables in the physiological cortisol profile included: peak 15.5 microg/dl (95% reference range 11.7-20.6), acrophase 0832 h (95% confidence interval 0759-0905), nadir less than 2 microg/dl (95% reference range 1.5-2.5), time of nadir 0018 h (95% confidence interval 2339-0058), and quiescent phase (below the mesor) 1943-0531 h.",Modified-release hydrocortisone to provide circadian cortisol profiles. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19223520/),h,0018,115677,DB01285,Corticotropin
,19223520,maximum observed concentration,MR-HC 15 mg demonstrated delayed and sustained release with a mean (sem) maximum observed concentration of 16.6 (1.4) microg/dl at 7.41 (0.57) h after drug.,Modified-release hydrocortisone to provide circadian cortisol profiles. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19223520/),[μg] / [dl],16.6,115678,DB01285,Corticotropin
,19223520,Bioavailability,"Bioavailability of MR-HC 5, 10, and 15 mg was 100, 79, and 86% that of immediate-release hydrocortisone.",Modified-release hydrocortisone to provide circadian cortisol profiles. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19223520/),%,100,115679,DB01285,Corticotropin
,19223520,Bioavailability,"Bioavailability of MR-HC 5, 10, and 15 mg was 100, 79, and 86% that of immediate-release hydrocortisone.",Modified-release hydrocortisone to provide circadian cortisol profiles. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19223520/),%,79,115680,DB01285,Corticotropin
,19223520,Bioavailability,"Bioavailability of MR-HC 5, 10, and 15 mg was 100, 79, and 86% that of immediate-release hydrocortisone.",Modified-release hydrocortisone to provide circadian cortisol profiles. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19223520/),%,86,115681,DB01285,Corticotropin
,10072679,Ki,Screening of our chemical library using a rat corticotropin-releasing hormone (CRH) receptor assay led to the discovery that 2-anilinopyrimidine 15-1 weakly displaced [125I]-0-Tyr-oCRH from rat frontal cortex homogenates when compared to the known peptide antagonist alpha-helical CRH(9-41) (Ki = 5700 nM vs 1 nM).,Non-peptide corticotropin-releasing hormone antagonists: syntheses and structure-activity relationships of 2-anilinopyrimidines and -triazines. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10072679/),nM,5700,117450,DB01285,Corticotropin
,10072679,Ki,Screening of our chemical library using a rat corticotropin-releasing hormone (CRH) receptor assay led to the discovery that 2-anilinopyrimidine 15-1 weakly displaced [125I]-0-Tyr-oCRH from rat frontal cortex homogenates when compared to the known peptide antagonist alpha-helical CRH(9-41) (Ki = 5700 nM vs 1 nM).,Non-peptide corticotropin-releasing hormone antagonists: syntheses and structure-activity relationships of 2-anilinopyrimidines and -triazines. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10072679/),nM,1,117451,DB01285,Corticotropin
,10072679,IC50,"Furthermore, 15-1 weakly inhibited CRH-stimulated adenylate cyclase activity in the same tissue, but it was less potent than alpha-helical CRH(9-41) (IC50 = 20 000 nM vs 250 nM).",Non-peptide corticotropin-releasing hormone antagonists: syntheses and structure-activity relationships of 2-anilinopyrimidines and -triazines. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10072679/),nM,20 000,117452,DB01285,Corticotropin
,10072679,IC50,"Furthermore, 15-1 weakly inhibited CRH-stimulated adenylate cyclase activity in the same tissue, but it was less potent than alpha-helical CRH(9-41) (IC50 = 20 000 nM vs 250 nM).",Non-peptide corticotropin-releasing hormone antagonists: syntheses and structure-activity relationships of 2-anilinopyrimidines and -triazines. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10072679/),nM,250,117453,DB01285,Corticotropin
,10072679,Ki,Compound 28-17 (mean hCRH1 Ki = 32 nM) had a significantly improved pharmacokinetic profile in the rat (19% oral bioavailability at 30 mg/kg) as well as in the dog (20% oral bioavailability at 5 mg/kg) relative to the early lead structures.,Non-peptide corticotropin-releasing hormone antagonists: syntheses and structure-activity relationships of 2-anilinopyrimidines and -triazines. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10072679/),nM,32,117454,DB01285,Corticotropin
,10072679,oral bioavailability,Compound 28-17 (mean hCRH1 Ki = 32 nM) had a significantly improved pharmacokinetic profile in the rat (19% oral bioavailability at 30 mg/kg) as well as in the dog (20% oral bioavailability at 5 mg/kg) relative to the early lead structures.,Non-peptide corticotropin-releasing hormone antagonists: syntheses and structure-activity relationships of 2-anilinopyrimidines and -triazines. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10072679/),%,19,117455,DB01285,Corticotropin
,10072679,oral bioavailability,Compound 28-17 (mean hCRH1 Ki = 32 nM) had a significantly improved pharmacokinetic profile in the rat (19% oral bioavailability at 30 mg/kg) as well as in the dog (20% oral bioavailability at 5 mg/kg) relative to the early lead structures.,Non-peptide corticotropin-releasing hormone antagonists: syntheses and structure-activity relationships of 2-anilinopyrimidines and -triazines. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10072679/),%,20,117456,DB01285,Corticotropin
,23672956,Cmax,"Serum cortisol increased rapidly and substantially after both i.m. and s.c. injections (Cmax: 110±29 vs 97±28 μg/dl, P=0.27, tmax: 66±51 vs 91±34 min, P=0.17, and tserum cortisol >36 μg/dl: 11±5 vs 22±11 min, P=0.004 respectively).",Subcutaneous hydrocortisone administration for emergency use in adrenal insufficiency. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23672956/),[μg] / [dl],110,118595,DB01285,Corticotropin
,23672956,Cmax,"Serum cortisol increased rapidly and substantially after both i.m. and s.c. injections (Cmax: 110±29 vs 97±28 μg/dl, P=0.27, tmax: 66±51 vs 91±34 min, P=0.17, and tserum cortisol >36 μg/dl: 11±5 vs 22±11 min, P=0.004 respectively).",Subcutaneous hydrocortisone administration for emergency use in adrenal insufficiency. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23672956/),[μg] / [dl],97,118596,DB01285,Corticotropin
,23672956,tmax,"Serum cortisol increased rapidly and substantially after both i.m. and s.c. injections (Cmax: 110±29 vs 97±28 μg/dl, P=0.27, tmax: 66±51 vs 91±34 min, P=0.17, and tserum cortisol >36 μg/dl: 11±5 vs 22±11 min, P=0.004 respectively).",Subcutaneous hydrocortisone administration for emergency use in adrenal insufficiency. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23672956/),min,66,118597,DB01285,Corticotropin
,23672956,tmax,"Serum cortisol increased rapidly and substantially after both i.m. and s.c. injections (Cmax: 110±29 vs 97±28 μg/dl, P=0.27, tmax: 66±51 vs 91±34 min, P=0.17, and tserum cortisol >36 μg/dl: 11±5 vs 22±11 min, P=0.004 respectively).",Subcutaneous hydrocortisone administration for emergency use in adrenal insufficiency. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23672956/),min,91,118598,DB01285,Corticotropin
,23672956,tserum,"Serum cortisol increased rapidly and substantially after both i.m. and s.c. injections (Cmax: 110±29 vs 97±28 μg/dl, P=0.27, tmax: 66±51 vs 91±34 min, P=0.17, and tserum cortisol >36 μg/dl: 11±5 vs 22±11 min, P=0.004 respectively).",Subcutaneous hydrocortisone administration for emergency use in adrenal insufficiency. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23672956/),min,11,118599,DB01285,Corticotropin
,23672956,tserum,"Serum cortisol increased rapidly and substantially after both i.m. and s.c. injections (Cmax: 110±29 vs 97±28 μg/dl, P=0.27, tmax: 66±51 vs 91±34 min, P=0.17, and tserum cortisol >36 μg/dl: 11±5 vs 22±11 min, P=0.004 respectively).",Subcutaneous hydrocortisone administration for emergency use in adrenal insufficiency. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23672956/),min,22,118600,DB01285,Corticotropin
,7951525,plasma half-lives (T1/2),"The disappearance of MCI-028 from plasma could be fitted to a biexponential decay curve, the plasma half-lives (T1/2) were 0.12 to 0.15 h for alpha phase, and 0.57 to 0.67 h for beta phase.",Diagnostic study of a synthetic human corticotropin-releasing hormone (hCRH) in healthy adult males: its plasma pharmacokinetics and the effects on the urinary excretion of steroid hormones. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7951525/),h,0.12 to 0.15,119376,DB01285,Corticotropin
,7951525,plasma half-lives (T1/2),"The disappearance of MCI-028 from plasma could be fitted to a biexponential decay curve, the plasma half-lives (T1/2) were 0.12 to 0.15 h for alpha phase, and 0.57 to 0.67 h for beta phase.",Diagnostic study of a synthetic human corticotropin-releasing hormone (hCRH) in healthy adult males: its plasma pharmacokinetics and the effects on the urinary excretion of steroid hormones. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7951525/),h,0.57 to 0.67,119377,DB01285,Corticotropin
,1513751,ED50,The ED50 of CRF for reducing pulmonary oedema was 3.2 (1.3-7.4) micrograms/kg s.c.,Epinephrine-induced pulmonary oedema in rats is inhibited by corticotropin-releasing factor. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1513751/),[μg] / [kg],3.2,119929,DB01285,Corticotropin
,22381334,absolute oral bioavailability,"BMS-562086 was orally bioavailable in rats, dogs, and chimpanzees, with an absolute oral bioavailability of 40.1, 58.8, and 58.5%, respectively.","In vitro and in vivo metabolism and pharmacokinetics of BMS-562086, a potent and orally bioavailable corticotropin-releasing factor-1 receptor antagonist. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22381334/),%,40.1,123218,DB01285,Corticotropin
,22381334,absolute oral bioavailability,"BMS-562086 was orally bioavailable in rats, dogs, and chimpanzees, with an absolute oral bioavailability of 40.1, 58.8, and 58.5%, respectively.","In vitro and in vivo metabolism and pharmacokinetics of BMS-562086, a potent and orally bioavailable corticotropin-releasing factor-1 receptor antagonist. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22381334/),%,58.8,123219,DB01285,Corticotropin
,22381334,absolute oral bioavailability,"BMS-562086 was orally bioavailable in rats, dogs, and chimpanzees, with an absolute oral bioavailability of 40.1, 58.8, and 58.5%, respectively.","In vitro and in vivo metabolism and pharmacokinetics of BMS-562086, a potent and orally bioavailable corticotropin-releasing factor-1 receptor antagonist. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22381334/),%,58.5,123220,DB01285,Corticotropin
,8165188,bioavailability,Nasal bioavailability was low (4.4%) compared to i.m. (24%).,Effect of formulation additives upon the intranasal bioavailability of a peptide drug: tetracosactide (ACTH1-24). ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8165188/),%,4.4,123390,DB01285,Corticotropin
,8165188,bioavailability,Nasal bioavailability was low (4.4%) compared to i.m. (24%).,Effect of formulation additives upon the intranasal bioavailability of a peptide drug: tetracosactide (ACTH1-24). ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8165188/),%,24,123391,DB01285,Corticotropin
,8165188,bioavailability,Poloxamer 407 addition did not improve drug kinetics profiles and showed a non-significant decrease in bioavailability (4%).,Effect of formulation additives upon the intranasal bioavailability of a peptide drug: tetracosactide (ACTH1-24). ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8165188/),%,4,123392,DB01285,Corticotropin
,8165188,Tmax,"The sodium glycocholate effect was very fast (Tmax = 5 min), but did not last long.",Effect of formulation additives upon the intranasal bioavailability of a peptide drug: tetracosactide (ACTH1-24). ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8165188/),min,5,123393,DB01285,Corticotropin
,8165188,bioavailability,"On the other hand, maximum tetracosactide levels in plasma were reached after 15 min for the formulation containing bacitracin as enhancer, and tetracosactide bioavailability was strongly increased, to 24%, i.e., as much as after an i.m. injection.",Effect of formulation additives upon the intranasal bioavailability of a peptide drug: tetracosactide (ACTH1-24). ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8165188/),%,24,123394,DB01285,Corticotropin
,15001641,t(1/2),The plasma Ucn-1 t(1/2) was 52 min based on a one-compartment model.,Urocortin-1 infusion in normal humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15001641/),min,52,127383,DB01285,Corticotropin
,16918954,MRTs,"Elimination of ACTH(1-24) was faster in HDT than in LDT (MRTs of 0.14 vs 0.37, respectively, P = 0.008), but plasma concentrations were higher up to 60 min cortisol production in HDT reaching a higher maximum concentration (Cmax: 1144 vs 960 nmol/l) but delayed in time (75 vs 52.5 min).","Profile, mean residence time of ACTH and cortisol responses after low and standard ACTH tests in healthy volunteers. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16918954/),,0.14,133997,DB01285,Corticotropin
,16918954,MRTs,"Elimination of ACTH(1-24) was faster in HDT than in LDT (MRTs of 0.14 vs 0.37, respectively, P = 0.008), but plasma concentrations were higher up to 60 min cortisol production in HDT reaching a higher maximum concentration (Cmax: 1144 vs 960 nmol/l) but delayed in time (75 vs 52.5 min).","Profile, mean residence time of ACTH and cortisol responses after low and standard ACTH tests in healthy volunteers. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16918954/),,0.37,133998,DB01285,Corticotropin
,16918954,maximum concentration (Cmax,"Elimination of ACTH(1-24) was faster in HDT than in LDT (MRTs of 0.14 vs 0.37, respectively, P = 0.008), but plasma concentrations were higher up to 60 min cortisol production in HDT reaching a higher maximum concentration (Cmax: 1144 vs 960 nmol/l) but delayed in time (75 vs 52.5 min).","Profile, mean residence time of ACTH and cortisol responses after low and standard ACTH tests in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16918954/),[nM] / [l],1144,133999,DB01285,Corticotropin
,16918954,maximum concentration (Cmax,"Elimination of ACTH(1-24) was faster in HDT than in LDT (MRTs of 0.14 vs 0.37, respectively, P = 0.008), but plasma concentrations were higher up to 60 min cortisol production in HDT reaching a higher maximum concentration (Cmax: 1144 vs 960 nmol/l) but delayed in time (75 vs 52.5 min).","Profile, mean residence time of ACTH and cortisol responses after low and standard ACTH tests in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16918954/),[nM] / [l],960,134000,DB01285,Corticotropin
,16918954,maximum concentration (Cmax,"Elimination of ACTH(1-24) was faster in HDT than in LDT (MRTs of 0.14 vs 0.37, respectively, P = 0.008), but plasma concentrations were higher up to 60 min cortisol production in HDT reaching a higher maximum concentration (Cmax: 1144 vs 960 nmol/l) but delayed in time (75 vs 52.5 min).","Profile, mean residence time of ACTH and cortisol responses after low and standard ACTH tests in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16918954/),,75,134001,DB01285,Corticotropin
,16918954,maximum concentration (Cmax,"Elimination of ACTH(1-24) was faster in HDT than in LDT (MRTs of 0.14 vs 0.37, respectively, P = 0.008), but plasma concentrations were higher up to 60 min cortisol production in HDT reaching a higher maximum concentration (Cmax: 1144 vs 960 nmol/l) but delayed in time (75 vs 52.5 min).","Profile, mean residence time of ACTH and cortisol responses after low and standard ACTH tests in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16918954/),,52.5,134002,DB01285,Corticotropin
,6313734,distribution,"The disappearance of IR-oCRF from plasma was characterized by a biexponential decay curve, with initial distribution and subsequent metabolic t 1/2 values of 6.1 +/- 0.5 and 55 +/- 3.8 min (mean +/- SE), respectively.","Plasma distribution, disappearance half-time, metabolic clearance rate, and degradation of synthetic ovine corticotropin-releasing factor in man. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6313734/),min,6.1,134989,DB01285,Corticotropin
,6313734,metabolic t 1/2,"The disappearance of IR-oCRF from plasma was characterized by a biexponential decay curve, with initial distribution and subsequent metabolic t 1/2 values of 6.1 +/- 0.5 and 55 +/- 3.8 min (mean +/- SE), respectively.","Plasma distribution, disappearance half-time, metabolic clearance rate, and degradation of synthetic ovine corticotropin-releasing factor in man. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6313734/),min,55,134990,DB01285,Corticotropin
,6313734,t 1/2,"In two subjects who were studied for 14-16 h after being given the largest dose of oCRF, there was third phase of disappearance, with a t 1/2 of 198 +/- 54 min.","Plasma distribution, disappearance half-time, metabolic clearance rate, and degradation of synthetic ovine corticotropin-releasing factor in man. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6313734/),min,198,134991,DB01285,Corticotropin
,6313734,MCR,The MCR of IR-oCRF was 2.4 +/- 0.2 ml/min . kg (146 +/- 12 l/m2 . day) and was relatively constant over a 3000-fold dose range.,"Plasma distribution, disappearance half-time, metabolic clearance rate, and degradation of synthetic ovine corticotropin-releasing factor in man. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6313734/),[ml] / [kg·min],2.4,134992,DB01285,Corticotropin
,6313734,MCR,The MCR of IR-oCRF was 2.4 +/- 0.2 ml/min . kg (146 +/- 12 l/m2 . day) and was relatively constant over a 3000-fold dose range.,"Plasma distribution, disappearance half-time, metabolic clearance rate, and degradation of synthetic ovine corticotropin-releasing factor in man. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6313734/),[l] / [d·m2],146,134993,DB01285,Corticotropin
,6313734,volume of distribution,The volume of distribution of IR-oCRF was 6.2 +/- 0.6 liters.,"Plasma distribution, disappearance half-time, metabolic clearance rate, and degradation of synthetic ovine corticotropin-releasing factor in man. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6313734/),l,6.2,134994,DB01285,Corticotropin
,19361209,IC(50),"This research resulted in the discovery of compound 13-15, which is a potent, selective CRF(1) antagonist (hCRF(1) IC(50) = 6.1 +/- 0.6 nM) with weak affinity for the CRF-binding protein and biogenic amine receptors.","Synthesis and structure-activity relationships of 8-(pyrid-3-yl)pyrazolo[1,5-a]-1,3,5-triazines: potent, orally bioavailable corticotropin releasing factor receptor-1 (CRF1) antagonists. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19361209/),nM,6.1,136409,DB01285,Corticotropin
,24697490,fub,"5. NVS-CRF38 is weakly bound to plasma proteins from rat (fub = 0.19), dog (fub = 0.25), monkey (fub = 0.20) and humans (fub = 0.23).","Preclinical metabolism and pharmacokinetics of NVS-CRF38, a potent and orally bioavailable corticotropin-releasing factor receptor 1 antagonist. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24697490/),,0.19,139065,DB01285,Corticotropin
,24697490,fub,"5. NVS-CRF38 is weakly bound to plasma proteins from rat (fub = 0.19), dog (fub = 0.25), monkey (fub = 0.20) and humans (fub = 0.23).","Preclinical metabolism and pharmacokinetics of NVS-CRF38, a potent and orally bioavailable corticotropin-releasing factor receptor 1 antagonist. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24697490/),,0,139066,DB01285,Corticotropin
,24697490,fub,"5. NVS-CRF38 is weakly bound to plasma proteins from rat (fub = 0.19), dog (fub = 0.25), monkey (fub = 0.20) and humans (fub = 0.23).","Preclinical metabolism and pharmacokinetics of NVS-CRF38, a potent and orally bioavailable corticotropin-releasing factor receptor 1 antagonist. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24697490/),,0.,139067,DB01285,Corticotropin
∼,24697490,extraction ratio,6. The hepatic clearance of NVS-CRF38 in humans is predicted to be low (extraction ratio ∼ 0.2) based on scaling from drug depletion profiles in hepatic microsomes.,"Preclinical metabolism and pharmacokinetics of NVS-CRF38, a potent and orally bioavailable corticotropin-releasing factor receptor 1 antagonist. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24697490/),,0.2,139068,DB01285,Corticotropin
,15943483,K(i),"Pyrrole- and pyrazole-based molecules 19g and 22a, respectively, were discovered that potently bind the recombinant CRF(1) receptor (K(i) = 3.5, 2.9 nM) and inhibit adrenocorticotropic hormone (ACTH) release from rat pituitary cell culture (IC(50) = 14, 6.8 nM).","Potent, orally active corticotropin-releasing factor receptor-1 antagonists containing a tricyclic pyrrolopyridine or pyrazolopyridine core. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15943483/),nM,3.5,142485,DB01285,Corticotropin
,15943483,K(i),"Pyrrole- and pyrazole-based molecules 19g and 22a, respectively, were discovered that potently bind the recombinant CRF(1) receptor (K(i) = 3.5, 2.9 nM) and inhibit adrenocorticotropic hormone (ACTH) release from rat pituitary cell culture (IC(50) = 14, 6.8 nM).","Potent, orally active corticotropin-releasing factor receptor-1 antagonists containing a tricyclic pyrrolopyridine or pyrazolopyridine core. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15943483/),nM,2.9,142486,DB01285,Corticotropin
,15943483,IC(50),"Pyrrole- and pyrazole-based molecules 19g and 22a, respectively, were discovered that potently bind the recombinant CRF(1) receptor (K(i) = 3.5, 2.9 nM) and inhibit adrenocorticotropic hormone (ACTH) release from rat pituitary cell culture (IC(50) = 14, 6.8 nM).","Potent, orally active corticotropin-releasing factor receptor-1 antagonists containing a tricyclic pyrrolopyridine or pyrazolopyridine core. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15943483/),nM,14,142487,DB01285,Corticotropin
,15943483,IC(50),"Pyrrole- and pyrazole-based molecules 19g and 22a, respectively, were discovered that potently bind the recombinant CRF(1) receptor (K(i) = 3.5, 2.9 nM) and inhibit adrenocorticotropic hormone (ACTH) release from rat pituitary cell culture (IC(50) = 14, 6.8 nM).","Potent, orally active corticotropin-releasing factor receptor-1 antagonists containing a tricyclic pyrrolopyridine or pyrazolopyridine core. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15943483/),nM,6.8,142488,DB01285,Corticotropin
,15943483,oral bioavailabity (F,"These compounds show good oral bioavailabity (F = 24%, 7.0%) and serum half-lives in rats (t(1/2) = 6.3, 12 h) and penetrate the rat brain ([brain]/[plasma] = 0.27, 0.52) but tend toward large volumes of distribution (V(D) = 38, 44 L kg(-1)) and rapid clearances (CL = 70, 43 mL min(-1) kg(-1)).","Potent, orally active corticotropin-releasing factor receptor-1 antagonists containing a tricyclic pyrrolopyridine or pyrazolopyridine core. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15943483/),%,24,142489,DB01285,Corticotropin
,15943483,oral bioavailabity (F,"These compounds show good oral bioavailabity (F = 24%, 7.0%) and serum half-lives in rats (t(1/2) = 6.3, 12 h) and penetrate the rat brain ([brain]/[plasma] = 0.27, 0.52) but tend toward large volumes of distribution (V(D) = 38, 44 L kg(-1)) and rapid clearances (CL = 70, 43 mL min(-1) kg(-1)).","Potent, orally active corticotropin-releasing factor receptor-1 antagonists containing a tricyclic pyrrolopyridine or pyrazolopyridine core. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15943483/),%,7.0,142490,DB01285,Corticotropin
,15943483,t(1/2),"These compounds show good oral bioavailabity (F = 24%, 7.0%) and serum half-lives in rats (t(1/2) = 6.3, 12 h) and penetrate the rat brain ([brain]/[plasma] = 0.27, 0.52) but tend toward large volumes of distribution (V(D) = 38, 44 L kg(-1)) and rapid clearances (CL = 70, 43 mL min(-1) kg(-1)).","Potent, orally active corticotropin-releasing factor receptor-1 antagonists containing a tricyclic pyrrolopyridine or pyrazolopyridine core. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15943483/),h,6.3,142491,DB01285,Corticotropin
,15943483,t(1/2),"These compounds show good oral bioavailabity (F = 24%, 7.0%) and serum half-lives in rats (t(1/2) = 6.3, 12 h) and penetrate the rat brain ([brain]/[plasma] = 0.27, 0.52) but tend toward large volumes of distribution (V(D) = 38, 44 L kg(-1)) and rapid clearances (CL = 70, 43 mL min(-1) kg(-1)).","Potent, orally active corticotropin-releasing factor receptor-1 antagonists containing a tricyclic pyrrolopyridine or pyrazolopyridine core. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15943483/),h,12,142492,DB01285,Corticotropin
,15943483,V(D),"These compounds show good oral bioavailabity (F = 24%, 7.0%) and serum half-lives in rats (t(1/2) = 6.3, 12 h) and penetrate the rat brain ([brain]/[plasma] = 0.27, 0.52) but tend toward large volumes of distribution (V(D) = 38, 44 L kg(-1)) and rapid clearances (CL = 70, 43 mL min(-1) kg(-1)).","Potent, orally active corticotropin-releasing factor receptor-1 antagonists containing a tricyclic pyrrolopyridine or pyrazolopyridine core. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15943483/),[l] / [kg],"38, 44",142493,DB01285,Corticotropin
,15943483,clearances (CL,"These compounds show good oral bioavailabity (F = 24%, 7.0%) and serum half-lives in rats (t(1/2) = 6.3, 12 h) and penetrate the rat brain ([brain]/[plasma] = 0.27, 0.52) but tend toward large volumes of distribution (V(D) = 38, 44 L kg(-1)) and rapid clearances (CL = 70, 43 mL min(-1) kg(-1)).","Potent, orally active corticotropin-releasing factor receptor-1 antagonists containing a tricyclic pyrrolopyridine or pyrazolopyridine core. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15943483/),[ml] / [kg·min],"70, 43",142494,DB01285,Corticotropin
less,18428980,water solubility,Antalarmin has a poor water solubility of less than 1 microg/mL and is weakly basic with an experimentally determined pK(a) of 5.0.,Preformulation and pharmacokinetic studies on antalarmin: a novel stress inhibitor. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18428980/),[μg] / [ml],1,153543,DB01285,Corticotropin
,18428980,pK(a),Antalarmin has a poor water solubility of less than 1 microg/mL and is weakly basic with an experimentally determined pK(a) of 5.0.,Preformulation and pharmacokinetic studies on antalarmin: a novel stress inhibitor. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18428980/),,5.0,153544,DB01285,Corticotropin
,18428980,drug loading capacity,"Four formulations, each with a targeted drug loading capacity of 100 mg/mL, show potential for oral administration.",Preformulation and pharmacokinetic studies on antalarmin: a novel stress inhibitor. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18428980/),[mg] / [ml],100,153545,DB01285,Corticotropin
<,31738804,peak serum cortisol level,AI was defined as a peak serum cortisol level of <500 nmol/L at 30 or 60 minutes after LDT or HDT.,Diagnostic performance of basal cortisol level at 0900-1300h in adrenal insufficiency. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31738804/),[nM] / [l],500,155209,DB01285,Corticotropin
,2840310,apparent half-life,The disappearance of RU486 and its metabolites conformed to a noncompartmental model with a mean apparent half-life of 53.7 +/- 6.9 hours.,Pharmacodynamics of the antiprogesterone RU486 in women after oral administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2840310/),h,53.7,162792,DB01285,Corticotropin
,2840310,apparent volume of distribution,"The mean apparent volume of distribution and clearance rate were 1.47 +/- 0.25 l/kg and 1.04 +/- 0.09 1/hour, respectively.",Pharmacodynamics of the antiprogesterone RU486 in women after oral administration. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2840310/),[l] / [kg],1.47,162793,DB01285,Corticotropin
,2840310,clearance rate,"The mean apparent volume of distribution and clearance rate were 1.47 +/- 0.25 l/kg and 1.04 +/- 0.09 1/hour, respectively.",Pharmacodynamics of the antiprogesterone RU486 in women after oral administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2840310/),[1] / [h],1.04,162794,DB01285,Corticotropin
,10887750,durations of,"Peak cortisol, progesterone and prostaglandin F2 alpha metabolite levels were reached at 80 +/- 10.0, 80 +/- 10.0 and 46.6 +/- 13.3 min after ACTH administration and the durations of the peaks were 181.8 +/- 19.8, 308.1 +/- 49.7 and 181.8 +/- 7.9 min, respectively.","Plasma levels of cortisol, progesterone, oestradiol-17 beta and prostaglandin F2 alpha metabolite after ACTH (Synacthen Depot) administration in ovariectomized gilts. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10887750/),min,181.8,162806,DB01285,Corticotropin
,10887750,durations of,"Peak cortisol, progesterone and prostaglandin F2 alpha metabolite levels were reached at 80 +/- 10.0, 80 +/- 10.0 and 46.6 +/- 13.3 min after ACTH administration and the durations of the peaks were 181.8 +/- 19.8, 308.1 +/- 49.7 and 181.8 +/- 7.9 min, respectively.","Plasma levels of cortisol, progesterone, oestradiol-17 beta and prostaglandin F2 alpha metabolite after ACTH (Synacthen Depot) administration in ovariectomized gilts. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10887750/),min,308.1,162807,DB01285,Corticotropin
,10887750,durations of,"Peak cortisol, progesterone and prostaglandin F2 alpha metabolite levels were reached at 80 +/- 10.0, 80 +/- 10.0 and 46.6 +/- 13.3 min after ACTH administration and the durations of the peaks were 181.8 +/- 19.8, 308.1 +/- 49.7 and 181.8 +/- 7.9 min, respectively.","Plasma levels of cortisol, progesterone, oestradiol-17 beta and prostaglandin F2 alpha metabolite after ACTH (Synacthen Depot) administration in ovariectomized gilts. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10887750/),min,181.8,162808,DB01285,Corticotropin
,28814143,overall IC50,"After eight days of dosing, post-adrenocorticotropic hormone challenge plasma aldosterone concentration increase was dose-dependently blunted by LY3045697 with high potency with a dose as low as 0.1 mg resulting in substantial effect, and with an overall IC50 of 0.38 ng/ml.",LY3045697: Results from two randomized clinical trials of a novel inhibitor of aldosterone synthase. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28814143/),[ng] / [ml],0.38,164327,DB01285,Corticotropin
,9834042,volume of distribution at steady state,"The volume of distribution at steady state was 9.81 +/- 3.0 and 15.61 +/- 2.9, and the clearance was 256 +/- 40 mL x min(-1) and 345 +/- 90 mL x min(-1) for the 10-minute and 180-minute intravenous infusion, respectively (P < .05).","Pharmacokinetics, cortisol release, and hemodynamics after intravenous and subcutaneous injection of human corticotropin-releasing factor in humans. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9834042/),,9.81,165736,DB01285,Corticotropin
,9834042,volume of distribution at steady state,"The volume of distribution at steady state was 9.81 +/- 3.0 and 15.61 +/- 2.9, and the clearance was 256 +/- 40 mL x min(-1) and 345 +/- 90 mL x min(-1) for the 10-minute and 180-minute intravenous infusion, respectively (P < .05).","Pharmacokinetics, cortisol release, and hemodynamics after intravenous and subcutaneous injection of human corticotropin-releasing factor in humans. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9834042/),,15.61,165737,DB01285,Corticotropin
,9834042,clearance,"The volume of distribution at steady state was 9.81 +/- 3.0 and 15.61 +/- 2.9, and the clearance was 256 +/- 40 mL x min(-1) and 345 +/- 90 mL x min(-1) for the 10-minute and 180-minute intravenous infusion, respectively (P < .05).","Pharmacokinetics, cortisol release, and hemodynamics after intravenous and subcutaneous injection of human corticotropin-releasing factor in humans. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9834042/),[ml] / [min],256,165738,DB01285,Corticotropin
,9834042,clearance,"The volume of distribution at steady state was 9.81 +/- 3.0 and 15.61 +/- 2.9, and the clearance was 256 +/- 40 mL x min(-1) and 345 +/- 90 mL x min(-1) for the 10-minute and 180-minute intravenous infusion, respectively (P < .05).","Pharmacokinetics, cortisol release, and hemodynamics after intravenous and subcutaneous injection of human corticotropin-releasing factor in humans. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9834042/),[ml] / [min],345,165739,DB01285,Corticotropin
,9834042,elimination half-life,Corresponding elimination half-life was 45 +/- 7 minutes and 37 +/- 10 minutes.,"Pharmacokinetics, cortisol release, and hemodynamics after intravenous and subcutaneous injection of human corticotropin-releasing factor in humans. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9834042/),min,45,165740,DB01285,Corticotropin
,9834042,elimination half-life,Corresponding elimination half-life was 45 +/- 7 minutes and 37 +/- 10 minutes.,"Pharmacokinetics, cortisol release, and hemodynamics after intravenous and subcutaneous injection of human corticotropin-releasing factor in humans. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9834042/),min,37,165741,DB01285,Corticotropin
,9834042,bioavailability,The bioavailability of hCRF after subcutaneous administration was 67% +/- 17%.,"Pharmacokinetics, cortisol release, and hemodynamics after intravenous and subcutaneous injection of human corticotropin-releasing factor in humans. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9834042/),%,67,165742,DB01285,Corticotropin
,26799632,half-life,"After multiple doses of 5-200 mg BI 135585, exposure (area under the curve) increased dose-proportionally and half-life was 55-65 h.","Safety, pharmacokinetics and pharmacodynamics of BI 135585, a selective 11β-hydroxysteroid dehydrogenase-1 (HSD1) inhibitor in humans: liver and adipose tissue 11β-HSD1 inhibition after acute and multiple administrations over 2 weeks. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26799632/),h,55-65,167430,DB01285,Corticotropin
,162880,metabolic clearance rate,"The mean metabolic clearance rate for the fetus and the ewe was 55 and 34 ml/min/kg respectively, giving a half-life in each case of about 1 min.",The clearance of ACTH from the plasma of adult and fetal sheep. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/162880/),[ml] / [kg·min],55,167796,DB01285,Corticotropin
,162880,metabolic clearance rate,"The mean metabolic clearance rate for the fetus and the ewe was 55 and 34 ml/min/kg respectively, giving a half-life in each case of about 1 min.",The clearance of ACTH from the plasma of adult and fetal sheep. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/162880/),[ml] / [kg·min],34,167797,DB01285,Corticotropin
,162880,half-life,"The mean metabolic clearance rate for the fetus and the ewe was 55 and 34 ml/min/kg respectively, giving a half-life in each case of about 1 min.",The clearance of ACTH from the plasma of adult and fetal sheep. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/162880/),min,1,167798,DB01285,Corticotropin
,2848706,half-lives,"Following the i.v. bolus, plasma levels rapidly declined biexponentially, with half-lives of 0.39 +/- 0.05 min for the alpha-phase and 3.84 +/- 1.5 min for the beta-phase (mean +/- SD).",The behaviorally active peptide ACTH 4-10: measurement in plasma and pharmacokinetics in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2848706/),min,0.39,174234,DB01285,Corticotropin
,2848706,half-lives,"Following the i.v. bolus, plasma levels rapidly declined biexponentially, with half-lives of 0.39 +/- 0.05 min for the alpha-phase and 3.84 +/- 1.5 min for the beta-phase (mean +/- SD).",The behaviorally active peptide ACTH 4-10: measurement in plasma and pharmacokinetics in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2848706/),min,3.84,174235,DB01285,Corticotropin
,2848706,steady-state levels,The constant rate i.v. infusion yielded steady-state levels between 0.74 and 5.06 ng/ml plasma.,The behaviorally active peptide ACTH 4-10: measurement in plasma and pharmacokinetics in man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2848706/),[ng] / [ml·plasma],0.74 and 5.06,174236,DB01285,Corticotropin
,2848706,maximal bioavailability,"Administered as intranasal spray, absorption of intact ACTH 4-10 was low and variable (maximal bioavailability 7.6%).",The behaviorally active peptide ACTH 4-10: measurement in plasma and pharmacokinetics in man. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2848706/),%,7.6,174237,DB01285,Corticotropin
,15735610,clearance,"Nicotine clearance was 1000 +/- 315 mL/min and 1047 +/- 271 mL/min in the follicular and luteal phases, respectively (geometric mean ratio, 1.06; 90% confidence interval, 0.87-1.29).",Influence of menstrual cycle on cytochrome P450 2A6 activity and cardiovascular effects of nicotine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15735610/),[ml] / [min],1000,176980,DB01285,Corticotropin
,15735610,clearance,"Nicotine clearance was 1000 +/- 315 mL/min and 1047 +/- 271 mL/min in the follicular and luteal phases, respectively (geometric mean ratio, 1.06; 90% confidence interval, 0.87-1.29).",Influence of menstrual cycle on cytochrome P450 2A6 activity and cardiovascular effects of nicotine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15735610/),[ml] / [min],1047,176981,DB01285,Corticotropin
,15735610,clearance,"Cotinine clearance was 44 +/- 20 mL/min and 55 +/- 42 mL/min in the follicular and luteal phases, respectively (geometric mean ratio, 1.13; 90% confidence interval, 0.90-1.41).",Influence of menstrual cycle on cytochrome P450 2A6 activity and cardiovascular effects of nicotine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15735610/),[ml] / [min],44,176982,DB01285,Corticotropin
,15735610,clearance,"Cotinine clearance was 44 +/- 20 mL/min and 55 +/- 42 mL/min in the follicular and luteal phases, respectively (geometric mean ratio, 1.13; 90% confidence interval, 0.90-1.41).",Influence of menstrual cycle on cytochrome P450 2A6 activity and cardiovascular effects of nicotine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15735610/),[ml] / [min],55,176983,DB01285,Corticotropin
,11331142,apparent elimination half life,Pharmacokinetic studies demonstrated that valproate has an apparent elimination half life of 17 minutes in rats after acute administration and that there is a nonlinear relationship between chronic dose and serum drug concentration.,Effects of sodium valproate on corticotropin-releasing factor systems in rat brain. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11331142/),min,17,185877,DB01285,Corticotropin
,15317828,total clearance,The total clearance of methylprednisolone for the female subjects was 15.6 +/- 5.99 L/h compared to the males with 21.5 +/- 8.67 L/h (P <.05).,Pharmacokinetics and pharmacodynamic response of methylprednisolone in premenopausal renal transplant recipients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15317828/),[l] / [h],15.6,187089,DB01285,Corticotropin
,15317828,total clearance,The total clearance of methylprednisolone for the female subjects was 15.6 +/- 5.99 L/h compared to the males with 21.5 +/- 8.67 L/h (P <.05).,Pharmacokinetics and pharmacodynamic response of methylprednisolone in premenopausal renal transplant recipients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15317828/),[l] / [h],21.5,187090,DB01285,Corticotropin
,15317828,a,Dose-normalized methylprednisolone a AUC was greater in women (66.1 +/- 19.8 ng*h/mL) than men (46.4 +/- 19.7 ng*h/mL) (P =.174).,Pharmacokinetics and pharmacodynamic response of methylprednisolone in premenopausal renal transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15317828/),[h·ng] / [ml],66.1,187091,DB01285,Corticotropin
,15317828,AUC,Dose-normalized methylprednisolone a AUC was greater in women (66.1 +/- 19.8 ng*h/mL) than men (46.4 +/- 19.7 ng*h/mL) (P =.174).,Pharmacokinetics and pharmacodynamic response of methylprednisolone in premenopausal renal transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15317828/),[h·ng] / [ml],66.1,187092,DB01285,Corticotropin
,15317828,AUC,Dose-normalized methylprednisolone a AUC was greater in women (66.1 +/- 19.8 ng*h/mL) than men (46.4 +/- 19.7 ng*h/mL) (P =.174).,Pharmacokinetics and pharmacodynamic response of methylprednisolone in premenopausal renal transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15317828/),[h·ng] / [ml],46.4,187093,DB01285,Corticotropin
,15317828,AUC,"Despite chronic steroid therapy, 9 of 13 women had a normal cortisol profile and an ACTH AUC of 299 +/- 102 pg*h/mL.",Pharmacokinetics and pharmacodynamic response of methylprednisolone in premenopausal renal transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15317828/),[h·pg] / [ml],299,187094,DB01285,Corticotropin
,7768373,drug delivery index,"The drug delivery index (a measure of relative targeting efficiency) was 6.7 and 8.6 in the cecal and colonic mucosa, respectively.",Colonic delivery of dexamethasone from a prodrug accelerates healing of colitis in rats without adrenal suppression. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7768373/),,6.7,187437,DB01285,Corticotropin
,7768373,drug delivery index,"The drug delivery index (a measure of relative targeting efficiency) was 6.7 and 8.6 in the cecal and colonic mucosa, respectively.",Colonic delivery of dexamethasone from a prodrug accelerates healing of colitis in rats without adrenal suppression. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7768373/),,8.6,187438,DB01285,Corticotropin
,16597550,elimination half-life,Plasma pharmacokinetics were dose-linear with an elimination half-life of 2.2 h.,Safety assessment of 4'-thio-beta-D-arabinofuranosylcytosine in the beagle dog suggests a drug-induced centrally mediated effect on the hypothalamic-pituitary-adrenal axis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16597550/),h,2.2,188462,DB01285,Corticotropin
,28063163,AUC,"Compared to immediate release hydrocortisone, free cortisol levels after 40 mg modified release hydrocortisone in ACC patients were significantly lower (12 ± 3 nmol/l; P = 0·03) resulting in a generally lower AUC (98 ± 21 vs 149 ± 37 nmol h/l; P = 0·02).",Immediate versus modified release hydrocortisone in mitotane-treated patients with adrenocortical cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28063163/),[h·nM] / [l],98,189416,DB01285,Corticotropin
,28063163,AUC,"Compared to immediate release hydrocortisone, free cortisol levels after 40 mg modified release hydrocortisone in ACC patients were significantly lower (12 ± 3 nmol/l; P = 0·03) resulting in a generally lower AUC (98 ± 21 vs 149 ± 37 nmol h/l; P = 0·02).",Immediate versus modified release hydrocortisone in mitotane-treated patients with adrenocortical cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28063163/),[h·nM] / [l],149,189417,DB01285,Corticotropin
,28806969,AUC0-inf,"Based on the plasma pharmacokinetics and urinary profiles, 20β-dihydroprednisolone was confirmed as the main prednisolone-derived metabolite, being detected in the biological fluids of all 12 bovines (plasma AUC0-inf of 121 h μg L-1 and urinary concentration > 0.695 μg L-1).",Pharmacokinetic and urinary profiling reveals the prednisolone/cortisol ratio as a valid biomarker for prednisolone administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28806969/),[h·μg] / [l],121,203536,DB01285,Corticotropin
,32593173,bioavailability,The bioavailability of Nasacthin003 was 14.3%.,Pharmacodynamic studies of nasal tetracosactide with salivary glucocorticoids for a noninvasive Short Synacthen Test. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32593173/),%,14.3,204915,DB01285,Corticotropin
,32593173,repeatability coefficient,"The repeatability coefficient at 60 minutes was 105 nmol/L for IV Synacthen and salivary cortisol and cortisone was 10.3 and 21.1 nmol/L, respectively.",Pharmacodynamic studies of nasal tetracosactide with salivary glucocorticoids for a noninvasive Short Synacthen Test. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32593173/),[nM] / [l],105,204916,DB01285,Corticotropin
,32593173,repeatability coefficient,"The repeatability coefficient at 60 minutes was 105 nmol/L for IV Synacthen and salivary cortisol and cortisone was 10.3 and 21.1 nmol/L, respectively.",Pharmacodynamic studies of nasal tetracosactide with salivary glucocorticoids for a noninvasive Short Synacthen Test. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32593173/),[nM] / [l],10.3,204917,DB01285,Corticotropin
,32593173,repeatability coefficient,"The repeatability coefficient at 60 minutes was 105 nmol/L for IV Synacthen and salivary cortisol and cortisone was 10.3 and 21.1 nmol/L, respectively.",Pharmacodynamic studies of nasal tetracosactide with salivary glucocorticoids for a noninvasive Short Synacthen Test. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32593173/),[nM] / [l],21.1,204918,DB01285,Corticotropin
,9811437,apparent distribution,"The apparent distribution and elimination rate constants (alpha and beta) were 7.4 +/- 2.7 x 10(-2) min(-1) and 5.5 +/- 3.8 x 10(-3) min(-1), respectively.","Pharmacokinetics of exogenous corticotropin in normal dogs, hospitalized dogs with non adrenal illness and adrenopathic dogs. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9811437/),1/[min],7.4,206414,DB01285,Corticotropin
,9811437,elimination rate constants,"The apparent distribution and elimination rate constants (alpha and beta) were 7.4 +/- 2.7 x 10(-2) min(-1) and 5.5 +/- 3.8 x 10(-3) min(-1), respectively.","Pharmacokinetics of exogenous corticotropin in normal dogs, hospitalized dogs with non adrenal illness and adrenopathic dogs. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9811437/),1/[min],7.4,206415,DB01285,Corticotropin
,9811437,elimination rate constants,"The apparent distribution and elimination rate constants (alpha and beta) were 7.4 +/- 2.7 x 10(-2) min(-1) and 5.5 +/- 3.8 x 10(-3) min(-1), respectively.","Pharmacokinetics of exogenous corticotropin in normal dogs, hospitalized dogs with non adrenal illness and adrenopathic dogs. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9811437/),1/[min],5.5,206416,DB01285,Corticotropin
,9811437,beta,"The apparent distribution and elimination rate constants (alpha and beta) were 7.4 +/- 2.7 x 10(-2) min(-1) and 5.5 +/- 3.8 x 10(-3) min(-1), respectively.","Pharmacokinetics of exogenous corticotropin in normal dogs, hospitalized dogs with non adrenal illness and adrenopathic dogs. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9811437/),1/[min],5.5,206417,DB01285,Corticotropin
,9811437,Area under the concentration-time curve (AUC),"Area under the concentration-time curve (AUC) was 2.91 +/- 0.78 x 10(4) pg x min/mL, mean residence time (MRT) was 45.0 +/- 12.2 min, the distribution half-life (t1/2alpha) was 9.4 min (harmonic mean), and the elimination half-life (t1/2beta) was 128 min (harmonic mean).","Pharmacokinetics of exogenous corticotropin in normal dogs, hospitalized dogs with non adrenal illness and adrenopathic dogs. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9811437/),[min·pg] / [ml],2.91,206418,DB01285,Corticotropin
,9811437,mean residence time (MRT),"Area under the concentration-time curve (AUC) was 2.91 +/- 0.78 x 10(4) pg x min/mL, mean residence time (MRT) was 45.0 +/- 12.2 min, the distribution half-life (t1/2alpha) was 9.4 min (harmonic mean), and the elimination half-life (t1/2beta) was 128 min (harmonic mean).","Pharmacokinetics of exogenous corticotropin in normal dogs, hospitalized dogs with non adrenal illness and adrenopathic dogs. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9811437/),min,45.0,206419,DB01285,Corticotropin
,9811437,distribution half-life (t1/2alpha),"Area under the concentration-time curve (AUC) was 2.91 +/- 0.78 x 10(4) pg x min/mL, mean residence time (MRT) was 45.0 +/- 12.2 min, the distribution half-life (t1/2alpha) was 9.4 min (harmonic mean), and the elimination half-life (t1/2beta) was 128 min (harmonic mean).","Pharmacokinetics of exogenous corticotropin in normal dogs, hospitalized dogs with non adrenal illness and adrenopathic dogs. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9811437/),min,9.4,206420,DB01285,Corticotropin
,9811437,elimination half-life (t1/2beta),"Area under the concentration-time curve (AUC) was 2.91 +/- 0.78 x 10(4) pg x min/mL, mean residence time (MRT) was 45.0 +/- 12.2 min, the distribution half-life (t1/2alpha) was 9.4 min (harmonic mean), and the elimination half-life (t1/2beta) was 128 min (harmonic mean).","Pharmacokinetics of exogenous corticotropin in normal dogs, hospitalized dogs with non adrenal illness and adrenopathic dogs. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9811437/),min,128,206421,DB01285,Corticotropin
,9811437,total body clearance of ACTH (ClB),The total body clearance of ACTH (ClB) was 1.83 +/- 0.46 x 10(4) mL x min/kg and volume of distribution (Vd(area)) was 30 +/- 15 L/kg.,"Pharmacokinetics of exogenous corticotropin in normal dogs, hospitalized dogs with non adrenal illness and adrenopathic dogs. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9811437/),[min·ml] / [kg],1.83,206422,DB01285,Corticotropin
,9811437,volume of distribution (Vd(area)),The total body clearance of ACTH (ClB) was 1.83 +/- 0.46 x 10(4) mL x min/kg and volume of distribution (Vd(area)) was 30 +/- 15 L/kg.,"Pharmacokinetics of exogenous corticotropin in normal dogs, hospitalized dogs with non adrenal illness and adrenopathic dogs. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9811437/),[l] / [kg],30,206423,DB01285,Corticotropin
,9811437,AUC,"In dogs with NAI, the AUC was 6.23 +/- 0.62 x 10(5) pg x min/mL, MRT was 38.7 +/- 12 min, the apparent elimination rate constant (k(el)) was 0.26 +/- 0.0017 min(-1) elimination half-life was 26.7 min, ClB was 0.84 +/- 0.1 x 10(4) mL/min/kg, and Vd(area) was 31.9 +/- 5.7 L/kg.","Pharmacokinetics of exogenous corticotropin in normal dogs, hospitalized dogs with non adrenal illness and adrenopathic dogs. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9811437/),[min·pg] / [ml],6.23,206424,DB01285,Corticotropin
,9811437,MRT,"In dogs with NAI, the AUC was 6.23 +/- 0.62 x 10(5) pg x min/mL, MRT was 38.7 +/- 12 min, the apparent elimination rate constant (k(el)) was 0.26 +/- 0.0017 min(-1) elimination half-life was 26.7 min, ClB was 0.84 +/- 0.1 x 10(4) mL/min/kg, and Vd(area) was 31.9 +/- 5.7 L/kg.","Pharmacokinetics of exogenous corticotropin in normal dogs, hospitalized dogs with non adrenal illness and adrenopathic dogs. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9811437/),min,38.7,206425,DB01285,Corticotropin
,9811437,apparent elimination rate constant (k(el)),"In dogs with NAI, the AUC was 6.23 +/- 0.62 x 10(5) pg x min/mL, MRT was 38.7 +/- 12 min, the apparent elimination rate constant (k(el)) was 0.26 +/- 0.0017 min(-1) elimination half-life was 26.7 min, ClB was 0.84 +/- 0.1 x 10(4) mL/min/kg, and Vd(area) was 31.9 +/- 5.7 L/kg.","Pharmacokinetics of exogenous corticotropin in normal dogs, hospitalized dogs with non adrenal illness and adrenopathic dogs. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9811437/),1/[min],0.26,206426,DB01285,Corticotropin
,9811437,elimination half-life,"In dogs with NAI, the AUC was 6.23 +/- 0.62 x 10(5) pg x min/mL, MRT was 38.7 +/- 12 min, the apparent elimination rate constant (k(el)) was 0.26 +/- 0.0017 min(-1) elimination half-life was 26.7 min, ClB was 0.84 +/- 0.1 x 10(4) mL/min/kg, and Vd(area) was 31.9 +/- 5.7 L/kg.","Pharmacokinetics of exogenous corticotropin in normal dogs, hospitalized dogs with non adrenal illness and adrenopathic dogs. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9811437/),min,26.7,206427,DB01285,Corticotropin
,9811437,ClB,"In dogs with NAI, the AUC was 6.23 +/- 0.62 x 10(5) pg x min/mL, MRT was 38.7 +/- 12 min, the apparent elimination rate constant (k(el)) was 0.26 +/- 0.0017 min(-1) elimination half-life was 26.7 min, ClB was 0.84 +/- 0.1 x 10(4) mL/min/kg, and Vd(area) was 31.9 +/- 5.7 L/kg.","Pharmacokinetics of exogenous corticotropin in normal dogs, hospitalized dogs with non adrenal illness and adrenopathic dogs. ",CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9811437/),[ml] / [kg·min],0.84,206428,DB01285,Corticotropin
,9811437,Vd(area),"In dogs with NAI, the AUC was 6.23 +/- 0.62 x 10(5) pg x min/mL, MRT was 38.7 +/- 12 min, the apparent elimination rate constant (k(el)) was 0.26 +/- 0.0017 min(-1) elimination half-life was 26.7 min, ClB was 0.84 +/- 0.1 x 10(4) mL/min/kg, and Vd(area) was 31.9 +/- 5.7 L/kg.","Pharmacokinetics of exogenous corticotropin in normal dogs, hospitalized dogs with non adrenal illness and adrenopathic dogs. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9811437/),[l] / [kg],31.9,206429,DB01285,Corticotropin
,9811437,AUC,"In dogs with HAC, AUC was 4.74 +/- 0.23 x 10(5) pg x min/mL, MRT was 20.4 min, k(el) was 0.034 +/- 0.009 min(-1), half-life was 20.4 min, CIB was 1.06 +/- 6.0 x 10(4) mL/min/kg and Vd(area) was 29.7 +/- 6.7 L/kg.","Pharmacokinetics of exogenous corticotropin in normal dogs, hospitalized dogs with non adrenal illness and adrenopathic dogs. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9811437/),[min·pg] / [ml],4.74,206430,DB01285,Corticotropin
,9811437,MRT,"In dogs with HAC, AUC was 4.74 +/- 0.23 x 10(5) pg x min/mL, MRT was 20.4 min, k(el) was 0.034 +/- 0.009 min(-1), half-life was 20.4 min, CIB was 1.06 +/- 6.0 x 10(4) mL/min/kg and Vd(area) was 29.7 +/- 6.7 L/kg.","Pharmacokinetics of exogenous corticotropin in normal dogs, hospitalized dogs with non adrenal illness and adrenopathic dogs. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9811437/),min,20.4,206431,DB01285,Corticotropin
,9811437,k(el),"In dogs with HAC, AUC was 4.74 +/- 0.23 x 10(5) pg x min/mL, MRT was 20.4 min, k(el) was 0.034 +/- 0.009 min(-1), half-life was 20.4 min, CIB was 1.06 +/- 6.0 x 10(4) mL/min/kg and Vd(area) was 29.7 +/- 6.7 L/kg.","Pharmacokinetics of exogenous corticotropin in normal dogs, hospitalized dogs with non adrenal illness and adrenopathic dogs. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9811437/),1/[min],0.034,206432,DB01285,Corticotropin
,9811437,half-life,"In dogs with HAC, AUC was 4.74 +/- 0.23 x 10(5) pg x min/mL, MRT was 20.4 min, k(el) was 0.034 +/- 0.009 min(-1), half-life was 20.4 min, CIB was 1.06 +/- 6.0 x 10(4) mL/min/kg and Vd(area) was 29.7 +/- 6.7 L/kg.","Pharmacokinetics of exogenous corticotropin in normal dogs, hospitalized dogs with non adrenal illness and adrenopathic dogs. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9811437/),min,20.4,206433,DB01285,Corticotropin
,9811437,CIB,"In dogs with HAC, AUC was 4.74 +/- 0.23 x 10(5) pg x min/mL, MRT was 20.4 min, k(el) was 0.034 +/- 0.009 min(-1), half-life was 20.4 min, CIB was 1.06 +/- 6.0 x 10(4) mL/min/kg and Vd(area) was 29.7 +/- 6.7 L/kg.","Pharmacokinetics of exogenous corticotropin in normal dogs, hospitalized dogs with non adrenal illness and adrenopathic dogs. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9811437/),[ml] / [kg·min],1.06,206434,DB01285,Corticotropin
,9811437,Vd(area),"In dogs with HAC, AUC was 4.74 +/- 0.23 x 10(5) pg x min/mL, MRT was 20.4 min, k(el) was 0.034 +/- 0.009 min(-1), half-life was 20.4 min, CIB was 1.06 +/- 6.0 x 10(4) mL/min/kg and Vd(area) was 29.7 +/- 6.7 L/kg.","Pharmacokinetics of exogenous corticotropin in normal dogs, hospitalized dogs with non adrenal illness and adrenopathic dogs. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9811437/),[l] / [kg],29.7,206435,DB01285,Corticotropin
,8440768,terminal half-life,"After the last dose, a mean terminal half-life of 35 hours was observed.","Evaluation of the pharmacokinetics and tolerability of tirilazad mesylate, a 21-aminosteroid free radical scavenger: II. Multiple-dose administration. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8440768/),h,35,212001,DB01285,Corticotropin
,19552437,IC(50),"Structure-activity relationship studies led to the identification of numerous potent analogues including 12p, a highly potent and selective CRF(1) receptor antagonist with an IC(50) value of 0.26 nM.","Synthesis, structure-activity relationships, and in vivo evaluation of N3-phenylpyrazinones as novel corticotropin-releasing factor-1 (CRF1) receptor antagonists. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19552437/),nM,0.26,213384,DB01285,Corticotropin
,3950871,half-times,"From in vitro assay, it was shown that hydrolysis of MPA to MP was rapid both in blood (half-times from 11.8 to 21.7 min) and in synovial fluid (half-times from 45.6 to 130.3 min).",Bovine plasma and synovial fluid kinetics of methylprednisolone and methylprednisolone acetate after intra-articular administration of methylprednisolone acetate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3950871/),min,11.8 to 21.7,224538,DB01285,Corticotropin
,3950871,half-times,"From in vitro assay, it was shown that hydrolysis of MPA to MP was rapid both in blood (half-times from 11.8 to 21.7 min) and in synovial fluid (half-times from 45.6 to 130.3 min).",Bovine plasma and synovial fluid kinetics of methylprednisolone and methylprednisolone acetate after intra-articular administration of methylprednisolone acetate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3950871/),min,45.6 to 130.3,224539,DB01285,Corticotropin
,3950871,systemic availability,"After intra-articular administration of MPA as a suspension (200 mg in toto), both MP and MPA decline very rapidly and, 24 hr after injection, less than 1% of the dose was present in the synovial fluid, but systemic availability of MP during the first 24 hr was only 30% of the dose.",Bovine plasma and synovial fluid kinetics of methylprednisolone and methylprednisolone acetate after intra-articular administration of methylprednisolone acetate. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3950871/),%,30,224540,DB01285,Corticotropin
,3950871,apparent half-time,"After this delay, the synovial fluid concentration decreased very slowly with an apparent half-time of 18 days.",Bovine plasma and synovial fluid kinetics of methylprednisolone and methylprednisolone acetate after intra-articular administration of methylprednisolone acetate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3950871/),d,18,224541,DB01285,Corticotropin
,18308795,response (area-under-the-curve,"Mean response (area-under-the-curve) over the first 4 hours (SD): 172.0 nmol/L (22.3) for placebo, 258.3 nmol/L (72.6) for 100 mg, 328.47 nmol/L (84.6) for 200 mg and 387.3 nmol/L (82.4) for 300 mg 5-HTP.",Pharmacology of rising oral doses of 5-hydroxytryptophan with carbidopa. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18308795/),[nM] / [l],172.0,224639,DB01285,Corticotropin
,18308795,response (area-under-the-curve,"Mean response (area-under-the-curve) over the first 4 hours (SD): 172.0 nmol/L (22.3) for placebo, 258.3 nmol/L (72.6) for 100 mg, 328.47 nmol/L (84.6) for 200 mg and 387.3 nmol/L (82.4) for 300 mg 5-HTP.",Pharmacology of rising oral doses of 5-hydroxytryptophan with carbidopa. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18308795/),[nM] / [l],258.3,224640,DB01285,Corticotropin
,18308795,response (area-under-the-curve,"Mean response (area-under-the-curve) over the first 4 hours (SD): 172.0 nmol/L (22.3) for placebo, 258.3 nmol/L (72.6) for 100 mg, 328.47 nmol/L (84.6) for 200 mg and 387.3 nmol/L (82.4) for 300 mg 5-HTP.",Pharmacology of rising oral doses of 5-hydroxytryptophan with carbidopa. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18308795/),[nM] / [l],328.47,224641,DB01285,Corticotropin
,18308795,response (area-under-the-curve,"Mean response (area-under-the-curve) over the first 4 hours (SD): 172.0 nmol/L (22.3) for placebo, 258.3 nmol/L (72.6) for 100 mg, 328.47 nmol/L (84.6) for 200 mg and 387.3 nmol/L (82.4) for 300 mg 5-HTP.",Pharmacology of rising oral doses of 5-hydroxytryptophan with carbidopa. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18308795/),[nM] / [l],387.3,224642,DB01285,Corticotropin
,18308795,oral clearance,5-HTP kinetics were adequately described using a one-compartment model with first-order absorption and a lag time (mean oral clearance 28 L/h interindividual coefficient of variation 31%).,Pharmacology of rising oral doses of 5-hydroxytryptophan with carbidopa. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18308795/),[l] / [h],28,224643,DB01285,Corticotropin
,6605972,plasma half-life,The plasma half-life of IR-CRF was 11.6 +/- 1.5 min (mean +/- SE) for the fast component and 73 +/- 8 min for the slow component.,Corticotropin-releasing factor: pharmacokinetics in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6605972/),min,11.6,226953,DB01285,Corticotropin
,6605972,plasma half-life,The plasma half-life of IR-CRF was 11.6 +/- 1.5 min (mean +/- SE) for the fast component and 73 +/- 8 min for the slow component.,Corticotropin-releasing factor: pharmacokinetics in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6605972/),min,73,226954,DB01285,Corticotropin
,6605972,MCR,"The MCR using the pulse injection technique was 95 +/- 11 liters/m2 X day, and the volume of distribution was 6.2 +/- 0.5 liters.",Corticotropin-releasing factor: pharmacokinetics in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6605972/),[l] / [d·m2],95,226955,DB01285,Corticotropin
,6605972,volume of distribution,"The MCR using the pulse injection technique was 95 +/- 11 liters/m2 X day, and the volume of distribution was 6.2 +/- 0.5 liters.",Corticotropin-releasing factor: pharmacokinetics in man. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6605972/),l,6.2,226956,DB01285,Corticotropin
,6605972,MCR,Continuous infusion of CRF gave approximately the same MCR (88 +/- 7 liters/m2 X day).,Corticotropin-releasing factor: pharmacokinetics in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6605972/),[l] / [d·m2],88,226957,DB01285,Corticotropin
,2170254,apparent clearance,CAF apparent clearance and apparent volume of distribution were lower in H(-) rats than in controls: 0.281 +/- 0.072 vs 0.455 +/- 0.165 l/kg/h (-38%; P less than 0.05) and 0.520 +/- 0.239 vs 1.28 +/- 0.266 l/kg (-59%; P less than 0.01) respectively.,Effect of hypophysectomy on caffeine elimination in rats. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2170254/),[l] / [h·kg],0.281,227308,DB01285,Corticotropin
,2170254,apparent clearance,CAF apparent clearance and apparent volume of distribution were lower in H(-) rats than in controls: 0.281 +/- 0.072 vs 0.455 +/- 0.165 l/kg/h (-38%; P less than 0.05) and 0.520 +/- 0.239 vs 1.28 +/- 0.266 l/kg (-59%; P less than 0.01) respectively.,Effect of hypophysectomy on caffeine elimination in rats. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2170254/),[l] / [h·kg],0.455,227309,DB01285,Corticotropin
,2170254,apparent volume of distribution,CAF apparent clearance and apparent volume of distribution were lower in H(-) rats than in controls: 0.281 +/- 0.072 vs 0.455 +/- 0.165 l/kg/h (-38%; P less than 0.05) and 0.520 +/- 0.239 vs 1.28 +/- 0.266 l/kg (-59%; P less than 0.01) respectively.,Effect of hypophysectomy on caffeine elimination in rats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2170254/),[l] / [kg],0.520,227310,DB01285,Corticotropin
,2170254,apparent volume of distribution,CAF apparent clearance and apparent volume of distribution were lower in H(-) rats than in controls: 0.281 +/- 0.072 vs 0.455 +/- 0.165 l/kg/h (-38%; P less than 0.05) and 0.520 +/- 0.239 vs 1.28 +/- 0.266 l/kg (-59%; P less than 0.01) respectively.,Effect of hypophysectomy on caffeine elimination in rats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2170254/),[l] / [kg],1.28,227311,DB01285,Corticotropin
,2170254,half-life,CAF half-life was lower in H(-) rats than in controls: 1.33 +/- 0.621 vs 2.12 +/- 0.676 h (-37%; P less than 0.01).,Effect of hypophysectomy on caffeine elimination in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2170254/),h,1.33,227312,DB01285,Corticotropin
,2170254,half-life,CAF half-life was lower in H(-) rats than in controls: 1.33 +/- 0.621 vs 2.12 +/- 0.676 h (-37%; P less than 0.01).,Effect of hypophysectomy on caffeine elimination in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2170254/),h,2.12,227313,DB01285,Corticotropin
,30944618,Ktrans,"The Ktrans, Kep and Ve of the microadenoma cases were 0.472±0.292/min, 0.765±0.359/min and 0.792±0.345, respectively.",Pharmacokinetic analysis for the differentiation of pituitary microadenoma subtypes through dynamic contrast-enhanced magnetic resonance imaging. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30944618/),1/[min],0.472,229087,DB01285,Corticotropin
,30944618,Kep,"The Ktrans, Kep and Ve of the microadenoma cases were 0.472±0.292/min, 0.765±0.359/min and 0.792±0.345, respectively.",Pharmacokinetic analysis for the differentiation of pituitary microadenoma subtypes through dynamic contrast-enhanced magnetic resonance imaging. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30944618/),1/[min],0.765,229088,DB01285,Corticotropin
,30944618,Ve,"The Ktrans, Kep and Ve of the microadenoma cases were 0.472±0.292/min, 0.765±0.359/min and 0.792±0.345, respectively.",Pharmacokinetic analysis for the differentiation of pituitary microadenoma subtypes through dynamic contrast-enhanced magnetic resonance imaging. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30944618/),,0.792,229089,DB01285,Corticotropin
,30944618,Ktrans,"The Ktrans, Kep and Ve of the normal control group were 0.902±0.238/min, 1.208±0.599/min and 0.928±0.378, respectively.",Pharmacokinetic analysis for the differentiation of pituitary microadenoma subtypes through dynamic contrast-enhanced magnetic resonance imaging. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30944618/),1/[min],0.902,229090,DB01285,Corticotropin
,30944618,Kep,"The Ktrans, Kep and Ve of the normal control group were 0.902±0.238/min, 1.208±0.599/min and 0.928±0.378, respectively.",Pharmacokinetic analysis for the differentiation of pituitary microadenoma subtypes through dynamic contrast-enhanced magnetic resonance imaging. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30944618/),1/[min],1.208,229091,DB01285,Corticotropin
,30944618,Ve,"The Ktrans, Kep and Ve of the normal control group were 0.902±0.238/min, 1.208±0.599/min and 0.928±0.378, respectively.",Pharmacokinetic analysis for the differentiation of pituitary microadenoma subtypes through dynamic contrast-enhanced magnetic resonance imaging. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30944618/),,0.928,229092,DB01285,Corticotropin
,186476,MCR,"In control subjects, the MCR (plasma) of both steroids increased by 29% (aldosterone: from 936 +/- 57 to 1204 +/- 55 l/day/m2, cortisol: from 205 +/- 12 to 264 +/- 17 l/day/m2 +/- SE) after ACTH (12 units/h) for 1 to 4 h, and by 20 and 32%, respectively, after cortisol (12 mg/h) for 1 to 2 h.",The effect of ACTH and cortisol on aldosterone and cortisol clearance and distribution in plasma and whole blood. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/186476/),[l] / [d·m2],936,234823,DB01285,Corticotropin
,186476,MCR,"In control subjects, the MCR (plasma) of both steroids increased by 29% (aldosterone: from 936 +/- 57 to 1204 +/- 55 l/day/m2, cortisol: from 205 +/- 12 to 264 +/- 17 l/day/m2 +/- SE) after ACTH (12 units/h) for 1 to 4 h, and by 20 and 32%, respectively, after cortisol (12 mg/h) for 1 to 2 h.",The effect of ACTH and cortisol on aldosterone and cortisol clearance and distribution in plasma and whole blood. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/186476/),[l] / [d·m2],1204,234824,DB01285,Corticotropin
,186476,MCR,"In control subjects, the MCR (plasma) of both steroids increased by 29% (aldosterone: from 936 +/- 57 to 1204 +/- 55 l/day/m2, cortisol: from 205 +/- 12 to 264 +/- 17 l/day/m2 +/- SE) after ACTH (12 units/h) for 1 to 4 h, and by 20 and 32%, respectively, after cortisol (12 mg/h) for 1 to 2 h.",The effect of ACTH and cortisol on aldosterone and cortisol clearance and distribution in plasma and whole blood. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/186476/),[l] / [d·m2],205,234825,DB01285,Corticotropin
,186476,MCR,"In control subjects, the MCR (plasma) of both steroids increased by 29% (aldosterone: from 936 +/- 57 to 1204 +/- 55 l/day/m2, cortisol: from 205 +/- 12 to 264 +/- 17 l/day/m2 +/- SE) after ACTH (12 units/h) for 1 to 4 h, and by 20 and 32%, respectively, after cortisol (12 mg/h) for 1 to 2 h.",The effect of ACTH and cortisol on aldosterone and cortisol clearance and distribution in plasma and whole blood. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/186476/),[l] / [d·m2],264,234826,DB01285,Corticotropin
,186476,MCR,"In contrast, aldosterone MCR (whole blood) did not change with ACTH or cortisol administration (from 1276 +/- 57 to 1330 +/- 59 l/day/m2), indicating that the plasma MCR increase results from a redistribution of aldosterone from plasma to red cells.",The effect of ACTH and cortisol on aldosterone and cortisol clearance and distribution in plasma and whole blood. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/186476/),[l] / [d·m2],1276,234827,DB01285,Corticotropin
,186476,MCR,"In contrast, aldosterone MCR (whole blood) did not change with ACTH or cortisol administration (from 1276 +/- 57 to 1330 +/- 59 l/day/m2), indicating that the plasma MCR increase results from a redistribution of aldosterone from plasma to red cells.",The effect of ACTH and cortisol on aldosterone and cortisol clearance and distribution in plasma and whole blood. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/186476/),[l] / [d·m2],1330,234828,DB01285,Corticotropin
,186476,extraction,"Aldosterone splanchnic extraction was 92 +/- 1% (n = 12) with normal morning cortisol levels, and extraction was unchanged after ACTH administration.",The effect of ACTH and cortisol on aldosterone and cortisol clearance and distribution in plasma and whole blood. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/186476/),%,92,234829,DB01285,Corticotropin
,186476,MCR,"For cortisol, however, the splanchnic extraction increased from 8 +/- 0.8% to 17.8 +/- 5.0%, and the MCR (whole blood) likewise increased by 15 to 31% (from 295 +/- 23 to 357 +/- 30 l/day/m2), after ACTH or cortisol administration.",The effect of ACTH and cortisol on aldosterone and cortisol clearance and distribution in plasma and whole blood. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/186476/),[l] / [d·m2],295,234830,DB01285,Corticotropin
,186476,MCR,"For cortisol, however, the splanchnic extraction increased from 8 +/- 0.8% to 17.8 +/- 5.0%, and the MCR (whole blood) likewise increased by 15 to 31% (from 295 +/- 23 to 357 +/- 30 l/day/m2), after ACTH or cortisol administration.",The effect of ACTH and cortisol on aldosterone and cortisol clearance and distribution in plasma and whole blood. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/186476/),[l] / [d·m2],357,234831,DB01285,Corticotropin
,16988492,peak plasma progesterone concentrations,"The means (+/- SE) of the peak plasma progesterone concentrations after the 3, 6, 12 and 25 IU ACTH challenge tests were 0.6 +/- 0.1, 1.3 +/- 0.4, 1.5 +/- 0.3 and 2.4 +/- 0.3 ng/ml, respectively.",Plasma cortisol and progesterone responses to low doses of adrenocorticotropic hormone in ovariectmized lactating cows. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16988492/),[ng] / [ml],0.6,248400,DB01285,Corticotropin
,16988492,peak plasma progesterone concentrations,"The means (+/- SE) of the peak plasma progesterone concentrations after the 3, 6, 12 and 25 IU ACTH challenge tests were 0.6 +/- 0.1, 1.3 +/- 0.4, 1.5 +/- 0.3 and 2.4 +/- 0.3 ng/ml, respectively.",Plasma cortisol and progesterone responses to low doses of adrenocorticotropic hormone in ovariectmized lactating cows. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16988492/),[ng] / [ml],1.3,248401,DB01285,Corticotropin
,16988492,peak plasma progesterone concentrations,"The means (+/- SE) of the peak plasma progesterone concentrations after the 3, 6, 12 and 25 IU ACTH challenge tests were 0.6 +/- 0.1, 1.3 +/- 0.4, 1.5 +/- 0.3 and 2.4 +/- 0.3 ng/ml, respectively.",Plasma cortisol and progesterone responses to low doses of adrenocorticotropic hormone in ovariectmized lactating cows. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16988492/),[ng] / [ml],1.5,248402,DB01285,Corticotropin
,16988492,peak plasma progesterone concentrations,"The means (+/- SE) of the peak plasma progesterone concentrations after the 3, 6, 12 and 25 IU ACTH challenge tests were 0.6 +/- 0.1, 1.3 +/- 0.4, 1.5 +/- 0.3 and 2.4 +/- 0.3 ng/ml, respectively.",Plasma cortisol and progesterone responses to low doses of adrenocorticotropic hormone in ovariectmized lactating cows. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16988492/),[ng] / [ml],2.4,248403,DB01285,Corticotropin
,16988492,peak plasma cortisol concentrations,"The means of the peak plasma cortisol concentrations in the 3 cows after the ACTH challenge were 14.0 +/- 1.5, 17.0 +/- 2.5, 23.3 +/- 3.0, and 33.3 +/- 7.0 ng/ml, respectively.",Plasma cortisol and progesterone responses to low doses of adrenocorticotropic hormone in ovariectmized lactating cows. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16988492/),[ng] / [ml],14.0,248404,DB01285,Corticotropin
,16988492,peak plasma cortisol concentrations,"The means of the peak plasma cortisol concentrations in the 3 cows after the ACTH challenge were 14.0 +/- 1.5, 17.0 +/- 2.5, 23.3 +/- 3.0, and 33.3 +/- 7.0 ng/ml, respectively.",Plasma cortisol and progesterone responses to low doses of adrenocorticotropic hormone in ovariectmized lactating cows. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16988492/),[ng] / [ml],17.0,248405,DB01285,Corticotropin
,16988492,peak plasma cortisol concentrations,"The means of the peak plasma cortisol concentrations in the 3 cows after the ACTH challenge were 14.0 +/- 1.5, 17.0 +/- 2.5, 23.3 +/- 3.0, and 33.3 +/- 7.0 ng/ml, respectively.",Plasma cortisol and progesterone responses to low doses of adrenocorticotropic hormone in ovariectmized lactating cows. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16988492/),[ng] / [ml],23.3,248406,DB01285,Corticotropin
,16988492,peak plasma cortisol concentrations,"The means of the peak plasma cortisol concentrations in the 3 cows after the ACTH challenge were 14.0 +/- 1.5, 17.0 +/- 2.5, 23.3 +/- 3.0, and 33.3 +/- 7.0 ng/ml, respectively.",Plasma cortisol and progesterone responses to low doses of adrenocorticotropic hormone in ovariectmized lactating cows. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16988492/),[ng] / [ml],33.3,248407,DB01285,Corticotropin
,25170571,ED50,"Compared with etomidate, CPMM was half as potent as a hypnotic (ED50 approximately 0.8 mg/kg), was more rapidly metabolized, and had a shorter duration of sedative-hypnotic action.",Advancing novel anesthetics: pharmacodynamic and pharmacokinetic studies of cyclopropyl-methoxycarbonyl metomidate in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25170571/),[mg] / [kg],0.8,248749,DB01285,Corticotropin
,25170571,half-time,"Adrenocortical recovery was faster in dogs after CPMM infusion versus etomidate infusion (half-time: 215 vs. 1,623 min, respectively).",Advancing novel anesthetics: pharmacodynamic and pharmacokinetic studies of cyclopropyl-methoxycarbonyl metomidate in dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25170571/),min,215,248750,DB01285,Corticotropin
,25170571,half-time,"Adrenocortical recovery was faster in dogs after CPMM infusion versus etomidate infusion (half-time: 215 vs. 1,623 min, respectively).",Advancing novel anesthetics: pharmacodynamic and pharmacokinetic studies of cyclopropyl-methoxycarbonyl metomidate in dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25170571/),min,"1,623",248751,DB01285,Corticotropin
,9396162,half-life,The half-life for the degradation of YLV in an aqueous solution of pH 7.4 at 37 degrees C was 35.9 h.,"Degradation of a novel tripeptide, tert-butoxycarbonyl-Tyr-Leu-Val-CH2Cl, with inhibitory effect on human leukocyte elastase in aqueous solution and in biological fluids. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9396162/),h,35.9,249556,DB01285,Corticotropin
,9396162,activation energies,"The activation energies of the degradation in aqueous solutions at pH 2.0, 4.8, and 7.4 were 24.6, 22.1 and 23.4 kcal/mol, respectively.","Degradation of a novel tripeptide, tert-butoxycarbonyl-Tyr-Leu-Val-CH2Cl, with inhibitory effect on human leukocyte elastase in aqueous solution and in biological fluids. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9396162/),[kcal] / [mol],24.6,249557,DB01285,Corticotropin
,9396162,activation energies,"The activation energies of the degradation in aqueous solutions at pH 2.0, 4.8, and 7.4 were 24.6, 22.1 and 23.4 kcal/mol, respectively.","Degradation of a novel tripeptide, tert-butoxycarbonyl-Tyr-Leu-Val-CH2Cl, with inhibitory effect on human leukocyte elastase in aqueous solution and in biological fluids. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9396162/),[kcal] / [mol],22.1,249558,DB01285,Corticotropin
,9396162,activation energies,"The activation energies of the degradation in aqueous solutions at pH 2.0, 4.8, and 7.4 were 24.6, 22.1 and 23.4 kcal/mol, respectively.","Degradation of a novel tripeptide, tert-butoxycarbonyl-Tyr-Leu-Val-CH2Cl, with inhibitory effect on human leukocyte elastase in aqueous solution and in biological fluids. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9396162/),[kcal] / [mol],23.4,249559,DB01285,Corticotropin
,9396162,half-life,"In a bovine pancreas alpha-chymotrypsin solution at 37 degrees C, the half-life of YLV was 15 min at 25.6 micrograms/ml of alpha-chymotrypsin solution.","Degradation of a novel tripeptide, tert-butoxycarbonyl-Tyr-Leu-Val-CH2Cl, with inhibitory effect on human leukocyte elastase in aqueous solution and in biological fluids. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9396162/),min,15,249560,DB01285,Corticotropin
,9396162,half-life,"In the rat plasma, the half-life of YLV was 42.4 min (YLV 26.7 micrograms/ml plasma), and in rat liver, lung and spleen homogenates, the degradation rate constants of YLV were 37.6, 10.3 and 23.5 times larger than that in plasma solution, respectively (all fluids containing 5 mg protein/ml).","Degradation of a novel tripeptide, tert-butoxycarbonyl-Tyr-Leu-Val-CH2Cl, with inhibitory effect on human leukocyte elastase in aqueous solution and in biological fluids. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9396162/),min,42.4,249561,DB01285,Corticotropin
,9396162,half-life,"In the rat plasma, the half-life of YLV was 42.4 min (YLV 26.7 micrograms/ml plasma), and in rat liver, lung and spleen homogenates, the degradation rate constants of YLV were 37.6, 10.3 and 23.5 times larger than that in plasma solution, respectively (all fluids containing 5 mg protein/ml).","Degradation of a novel tripeptide, tert-butoxycarbonyl-Tyr-Leu-Val-CH2Cl, with inhibitory effect on human leukocyte elastase in aqueous solution and in biological fluids. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9396162/),,26,249562,DB01285,Corticotropin
,1319455,half-life,"In man, the half-life of hCRH (30.5 +/- 3.3 min; mean +/- S.E.M.) was significantly (P less than 0.001) less than that of oCRH (42.8 +/- 6.4 min).",A comparison of the clearance of ovine and human corticotrophin-releasing hormone (CRH) in man and sheep: a possible role for CRH-binding protein. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1319455/),min,30.5,266613,DB01285,Corticotropin
,1319455,half-life,"In man, the half-life of hCRH (30.5 +/- 3.3 min; mean +/- S.E.M.) was significantly (P less than 0.001) less than that of oCRH (42.8 +/- 6.4 min).",A comparison of the clearance of ovine and human corticotrophin-releasing hormone (CRH) in man and sheep: a possible role for CRH-binding protein. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1319455/),min,42.8,266614,DB01285,Corticotropin
,1319455,half-life,"In sheep, there was no significant difference between the half-life of hCRH (46.5 +/- 7.2 min) and that of oCRH (39.8 +/- 10.1 min); these half-lives were also significantly (P less than 0.001) longer than that of hCRH in man.",A comparison of the clearance of ovine and human corticotrophin-releasing hormone (CRH) in man and sheep: a possible role for CRH-binding protein. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1319455/),min,46.5,266615,DB01285,Corticotropin
,1319455,half-life,"In sheep, there was no significant difference between the half-life of hCRH (46.5 +/- 7.2 min) and that of oCRH (39.8 +/- 10.1 min); these half-lives were also significantly (P less than 0.001) longer than that of hCRH in man.",A comparison of the clearance of ovine and human corticotrophin-releasing hormone (CRH) in man and sheep: a possible role for CRH-binding protein. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1319455/),min,39.8,266616,DB01285,Corticotropin
,6319844,t 1/2,"The MCR and hNT and hACTH were 3.01 +/- 0.20 ml/min (M +/- S.D., N = 4) and 2.04 +/- 0.06 ml/min, respectively (p less than 0.05), The curve for the disappearance rate of IR-hNT was triphasic (rapid t 1/2 = 0.96 +/- 0.39 min, intermediate t 1/2 = 6.7 +/- 2.25 min, and slow t 1/2 = 74 +/- 15.8 min), while that of IR-ACTH was biphasic (rapid t 1/2 = 3.3 +/- 0.68 min, and slow t 1/2 = 41.5 +/- 3.03 min) as analyzed by the non-linear least-squares methods.",Metabolic clearance rate and half-time disappearance rate of human N-terminal and adrenocorticotropin of pro-opiomelanocortin in the rat: a comparative study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6319844/),min,0.96,270170,DB01285,Corticotropin
,6319844,t 1/2,"The MCR and hNT and hACTH were 3.01 +/- 0.20 ml/min (M +/- S.D., N = 4) and 2.04 +/- 0.06 ml/min, respectively (p less than 0.05), The curve for the disappearance rate of IR-hNT was triphasic (rapid t 1/2 = 0.96 +/- 0.39 min, intermediate t 1/2 = 6.7 +/- 2.25 min, and slow t 1/2 = 74 +/- 15.8 min), while that of IR-ACTH was biphasic (rapid t 1/2 = 3.3 +/- 0.68 min, and slow t 1/2 = 41.5 +/- 3.03 min) as analyzed by the non-linear least-squares methods.",Metabolic clearance rate and half-time disappearance rate of human N-terminal and adrenocorticotropin of pro-opiomelanocortin in the rat: a comparative study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6319844/),min,6.7,270171,DB01285,Corticotropin
,6319844,t 1/2,"The MCR and hNT and hACTH were 3.01 +/- 0.20 ml/min (M +/- S.D., N = 4) and 2.04 +/- 0.06 ml/min, respectively (p less than 0.05), The curve for the disappearance rate of IR-hNT was triphasic (rapid t 1/2 = 0.96 +/- 0.39 min, intermediate t 1/2 = 6.7 +/- 2.25 min, and slow t 1/2 = 74 +/- 15.8 min), while that of IR-ACTH was biphasic (rapid t 1/2 = 3.3 +/- 0.68 min, and slow t 1/2 = 41.5 +/- 3.03 min) as analyzed by the non-linear least-squares methods.",Metabolic clearance rate and half-time disappearance rate of human N-terminal and adrenocorticotropin of pro-opiomelanocortin in the rat: a comparative study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6319844/),min,74,270172,DB01285,Corticotropin
,6319844,t 1/2,"The MCR and hNT and hACTH were 3.01 +/- 0.20 ml/min (M +/- S.D., N = 4) and 2.04 +/- 0.06 ml/min, respectively (p less than 0.05), The curve for the disappearance rate of IR-hNT was triphasic (rapid t 1/2 = 0.96 +/- 0.39 min, intermediate t 1/2 = 6.7 +/- 2.25 min, and slow t 1/2 = 74 +/- 15.8 min), while that of IR-ACTH was biphasic (rapid t 1/2 = 3.3 +/- 0.68 min, and slow t 1/2 = 41.5 +/- 3.03 min) as analyzed by the non-linear least-squares methods.",Metabolic clearance rate and half-time disappearance rate of human N-terminal and adrenocorticotropin of pro-opiomelanocortin in the rat: a comparative study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6319844/),min,3.3,270173,DB01285,Corticotropin
,6319844,t 1/2,"The MCR and hNT and hACTH were 3.01 +/- 0.20 ml/min (M +/- S.D., N = 4) and 2.04 +/- 0.06 ml/min, respectively (p less than 0.05), The curve for the disappearance rate of IR-hNT was triphasic (rapid t 1/2 = 0.96 +/- 0.39 min, intermediate t 1/2 = 6.7 +/- 2.25 min, and slow t 1/2 = 74 +/- 15.8 min), while that of IR-ACTH was biphasic (rapid t 1/2 = 3.3 +/- 0.68 min, and slow t 1/2 = 41.5 +/- 3.03 min) as analyzed by the non-linear least-squares methods.",Metabolic clearance rate and half-time disappearance rate of human N-terminal and adrenocorticotropin of pro-opiomelanocortin in the rat: a comparative study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6319844/),min,41.5,270174,DB01285,Corticotropin
,16297619,oral bioavailabilities,Selected compounds were examined in a rat pharmacokinetic study and were found to have oral bioavailabilities ranging from 16 to 35%.,Synthesis and evaluation of 2-anilino-3-phenylsulfonyl-6-methylpyridines as corticotropin-releasing factor1 receptor ligands. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16297619/),%,16 to 35,270549,DB01285,Corticotropin
,9506757,Peak cocaine plasma levels,Peak cocaine plasma levels averaged 101.2 +/- 14.6 ng/mL.,Concurrent pharmacokinetic analysis of plasma cocaine and adrenocorticotropic hormone in men. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9506757/),[ng] / [ml],101.2,273514,DB01285,Corticotropin
,9506757,t(max) (observed time to maximum concentration),Pharmacokinetic analysis showed that the t(max) (observed time to maximum concentration) values for cocaine (6.0 +/- 1.4 min) and ACTH (7.3 +/- 1.2 min) were almost identical.,Concurrent pharmacokinetic analysis of plasma cocaine and adrenocorticotropic hormone in men. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9506757/),min,6.0,273515,DB01285,Corticotropin
,9506757,t(max) (observed time to maximum concentration),Pharmacokinetic analysis showed that the t(max) (observed time to maximum concentration) values for cocaine (6.0 +/- 1.4 min) and ACTH (7.3 +/- 1.2 min) were almost identical.,Concurrent pharmacokinetic analysis of plasma cocaine and adrenocorticotropic hormone in men. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9506757/),min,7.3,273516,DB01285,Corticotropin
,9506757,area under the curve,"The area under the curve for plasma cocaine was 6463 +/- 1070 ng/min x mL, and the area under the curve for ACTH was 1873 +/- 188 pmol/min x L.",Concurrent pharmacokinetic analysis of plasma cocaine and adrenocorticotropic hormone in men. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9506757/),[ng] / [min·ml],6463,273517,DB01285,Corticotropin
,9506757,area under the curve,"The area under the curve for plasma cocaine was 6463 +/- 1070 ng/min x mL, and the area under the curve for ACTH was 1873 +/- 188 pmol/min x L.",Concurrent pharmacokinetic analysis of plasma cocaine and adrenocorticotropic hormone in men. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9506757/),[pM] / [l·min],1873,273518,DB01285,Corticotropin
,9506757,half-life,"The mean half-life for plasma cocaine was 46.7 +/- 4.0 min, and that for ACTH was 35.8 +/- 5.1 min.",Concurrent pharmacokinetic analysis of plasma cocaine and adrenocorticotropic hormone in men. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9506757/),min,46.7,273519,DB01285,Corticotropin
,9506757,half-life,"The mean half-life for plasma cocaine was 46.7 +/- 4.0 min, and that for ACTH was 35.8 +/- 5.1 min.",Concurrent pharmacokinetic analysis of plasma cocaine and adrenocorticotropic hormone in men. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9506757/),min,35.8,273520,DB01285,Corticotropin
